

# Biocompatible ligand balancing in transition metal coordination enables benign in-cell protein arylation

Received: 19 July 2024

Accepted: 28 October 2025

Published online: 07 January 2026

Check for updates

Xiaping Fu <sup>1,2,6</sup>, Weibing Liu <sup>1,2,6</sup>, Yana Demyanenko <sup>1,2</sup>, Wael Kamel<sup>3</sup>, Ravi Teja Ravi<sup>1</sup>, Vincenzo Ruscica <sup>3</sup>, Marko Noerenberg <sup>3</sup>, Xuejian Yin <sup>1,2</sup>, Yi Jiang<sup>1,2</sup>, Chi-Hang Fan <sup>1,2</sup>, Katarzyna M. Kowalczyk<sup>1,2</sup>, Eduardo Kitano <sup>1,2</sup>, James Morgan<sup>4</sup>, Simon Aldridge <sup>4</sup>, Maud Dumoux <sup>1</sup>, Alfredo Castello<sup>3</sup>, Shabaz Mohammed <sup>1,4,5</sup> ✉ & Benjamin G. Davis <sup>1,2,4</sup> ✉

Metal-mediated chemistries now find increasing application in *in vitro* biomolecule modification. However, the perceived and potential toxicity of some metals has limited the application of organometallic reagents in more complex biological settings such as inside living cells. Ligands play a crucial role in modulating both the reactivity and availability of transition metals. Here we reveal that organonickel-mediated S-arylation tolerates flexible chelation with biocompatible ligands without destroying the chemical reactivity of corresponding aryl-nickel reagents, enabling the creation of safe, site-selective C–S-bond-forming arylation manifolds. These balanced systems prove sufficiently benign for use on diverse protein substrates *in vitro* and in living prokaryotic and eukaryotic cells. This, in turn, enables deep chemical surveys of reactive cysteines in human cells with sensitivity sufficient to detect covalently targetable proteins from emerging intracellular viral and bacterial pathogens. Biocompatible ligand balancing thus offers a path to the broader use of transition metals in living systems.

The benign application of exogenous organometallics and/or metal-local catalysis in living systems remains rare<sup>1,2</sup>. While the utilization of the many powerful processes that can be driven by abiotic metals in classic synthetic chemistry, supported by experimental observations of potentially benign utility<sup>3–5</sup>, has suggested roles in driving new reactivities and hence the programming of biomolecule function in cells<sup>2,6–9</sup>, their use to date has typically been restricted to isolated biomolecules *in vitro* or to the manipulation (largely cleavage) of small molecules. Conjugative reactions that could allow the broad-scale covalent surveying and even modulation of cellular proteomes present an exciting unmet challenge.

Transition metal biocatalysis (and associated biotic, normally first-row, metals) is essential in many widespread metabolic processes<sup>10</sup>. However, binary notions about the toxicity of such metals

(and their second row counterparts) have perhaps incorrectly guided strategic thinking. Given the many roles of metals as cofactors, a strategy instead where their activities (target versus off-target) might be ‘balanced’ in a biocompatible manner would expand modes of biological (even perhaps *in-cell* or *in vivo*) reactivity and utility.

At a reductionist level, the various physiological modes of toxicity are ones of unwanted side reactivity. Ligand control is an obvious and immediate strategy exploited by nature to limit the side reactivity of metals. Yet, it has been essentially unexplored for control of desired *de novo* chemical reactivity in living systems. This is all the more surprising given the fact that ‘chelation’ of perceived toxic heavy metals is a long-standing strategy in therapeutic medicine<sup>11</sup> that succeeds, in part, via a changed ligand environment of metals *in vivo*. In addition,

<sup>1</sup>The Rosalind Franklin Institute, Harwell, UK. <sup>2</sup>Department of Pharmacology, University of Oxford, Oxford, UK. <sup>3</sup>MRC–University of Glasgow Centre for Virus Research, Glasgow, UK. <sup>4</sup>Department of Chemistry, University of Oxford, Oxford, UK. <sup>5</sup>Department of Biochemistry, University of Oxford, Oxford, UK. <sup>6</sup>These authors contributed equally: Xiaping Fu, Weibing Liu. ✉e-mail: [Shabaz.Mohammed@chem.ox.ac.uk](mailto:Shabaz.Mohammed@chem.ox.ac.uk); [Ben.Davis@rfi.ac.uk](mailto:Ben.Davis@rfi.ac.uk)

given the ubiquity of metals in variously liganded states in nature, new modes of reactivity within living systems could exploit selectivity based on ligand exchange; ligand-variation could enable selectivity that would exploit natural transition metal coordination sites, for example, for directed abiotic catalysis<sup>12</sup>.

The ligand states of the abiotic metals that have been used thus far in living systems are not fully understood, despite being likely to modulate<sup>3,13,14</sup> both reactivity and possible transport, even if this may only be to preferred catalytic sites on biomolecule targets<sup>12</sup>. Although exogenous protein carriers have been suggested to control metal catalysis in living systems<sup>15</sup>, a primary focus for pioneering small-molecule chemistry applied in cells<sup>8</sup> has instead been on heterogeneous metalocatalysis (for example, via polymer- or particle-based delivery vehicles)<sup>9,16–20</sup>. Yet, for free-ranging editing of biomolecules (and full application of small-molecule methodology), soluble homogeneous catalysts and/or organometallics will probably be a preferred mode of application. This would enable opportunities for ligand control not afforded to the same extent by heterogeneous modes—these include the ‘biocompatible ligand balancing’ that we suggest here.

Nickel is an essential micronutrient driving diverse enzymatic activities<sup>21,22</sup>, yet can be toxic<sup>23</sup>. This balance between reactivity and unwanted side reactions (‘balanced’ biological compatibility) is at the heart of the selectivity that will be required for ‘editing’ biology through free-ranging synthetic chemical methodology<sup>1</sup> and yet has been relatively poorly explored in the emerging field of chemical protein editing, despite the highlighted potential for metalocatalysis<sup>6</sup>. Indeed, although possible modes of nickel toxicity remain relatively poorly understood<sup>24–26</sup>, logical mechanisms centre around unwanted sequestration and/or associated redox properties. In several cellular systems homeostatic mechanisms have emerged to regulate nickel toxicity<sup>23</sup>. Maintaining the essential role of nickel relies upon differential affinity for endogenous ligands—the utility of the metal centre in required chemistries is ‘balanced’ by sufficient ligand affinity to guide it away from unwanted pathways.

Notably, and remarkably, nickel centres are known in rare biocatalytic systems that mediate reductive elimination to drive C–S bond formation<sup>27</sup>. Moreover, in these systems nickel is labile<sup>28</sup> and transportable, yet used efficiently; associated specific helper proteins for such enzymes mediate careful localization and hence the loading of nickel via protein co-complexes that ‘hand over’ the metal<sup>29–31</sup>. Such<sup>31</sup> and other<sup>32</sup> processes also mediate cellular nickel uptake. Although natural, enzymatic posttranslational C–S-bond-forming protein alkylation chemistries are known<sup>33–35</sup>, none appear to involve nickel.

Over the past few decades, the toolbox for cysteine modification in proteins has expanded considerably<sup>36–38</sup>. C–S bond formation<sup>39</sup> is a primary mode of reaction and, beyond more traditional organic methods such as conjugate addition or alkylation of Cys thiol (see also Supplementary Note 1 for an extended discussion of use in cysteinome profiling<sup>40</sup>), S-arylation has emerged as a useful strategy<sup>41</sup>. In vitro approaches applied to isolated biomolecules have included electron-deficient benzenoid<sup>42,43</sup> and hetero<sup>44–47</sup> aryls for S<sub>N</sub>2Ar reactions<sup>41</sup> and for metal-mediated arylation<sup>48</sup>.

Compared with S<sub>N</sub>2Ar-type S-arylation reagents, organometallic aryl-metal reagents or intermediates (either preformed and used stoichiometrically<sup>49,50</sup> or formed in situ catalytically<sup>12</sup>) can tolerate a wider range of aryl motifs, less limited by needed electronics. Despite this potential, currently reported aryl-metal manifolds for protein S-arylation have been dominated by those mediated by aryl palladium<sup>12,49</sup> and aryl gold complexes<sup>50,51</sup>. During the course of this work, a pioneering example of in situ nickel catalysis was also reported<sup>52</sup>. While these methods applied to isolated biomolecules have found elegant applications as diverse as, for example, antibody–drug conjugate development, cross-linking/stapling and

radiolabelling<sup>52–56</sup>, their application inside cells or living systems has not yet been shown.

Inspired (Fig. 1a) by the evolved, natural use of flexibly but carefully liganded nickel, we explored a biomimetic concept of ‘biocompatible ligand balancing’ in chemical protein editing as a strategy for maintaining sufficient useful reactivity in novel chemistries that might be applicable to the editing of living systems, while avoiding off-target effects. Here we reveal that, despite very different C–S chemistries to those found naturally, the mechanistic flexibility of nickel’s geometry in oxidative addition–reductive elimination pathways, coupled with designed chelation, seemingly enables minimal sequestration allowing the development of benign nickel-mediated protein arylation, applicable even inside living cells.


## Results

### Design of ligand-balanced protein arylation reagents

Nature employs a flexible ligand environment that enables nickel’s reactivity and transport<sup>28–31</sup>. Moreover, the active site environments that mediate biocatalytic reductive elimination to form C–S bonds<sup>27</sup> contrast with the reported requirement of current small-molecule aryl palladium and aryl gold reagents that allow protein S-arylation. These instead require sterically bulky phosphine ligands that promote reductive elimination to form the desired S-arylated product<sup>49–51,53</sup> and concomitant monodentate complexes with potentially limited permeability. These observations seemingly lowered the possibility for biocompatible ligand balancing in existing palladium- and gold-based manifolds and suggested inherently greater ligand variation around nickel. This was further supported by known reductive elimination in Ni<sup>0/II</sup> systems for small-molecule synthesis<sup>57,58</sup> and the strong potential shown by application to unprotected peptides<sup>59–61</sup> albeit via different catalytic processes (nickel/photoredox<sup>59</sup> or from arylboronic acids precursors<sup>60</sup>) even with apparently ligand-free metal sources (for example, Ni(OAc)<sub>2</sub> or NiCl<sub>2</sub>)<sup>60,61</sup>. Notably, stable nickel precatalysts have shown utility in reductive elimination Ni<sup>0/II</sup> systems that arylate nucleophilic (NH) heteroatoms<sup>57</sup>; Ni<sup>0/II</sup> systems enable metathesis between small-molecule aryl nitriles and thioethers, implying functional reductive elimination to Ar–SR<sup>58</sup>.

Together these suggested a possible flexibility in ligand use that would allow the design of a range of aryl-nickel reagents in which the ligand could minimize unwanted sequestration within biological milieu yet would also allow retention of reactivity with protein thiol nucleophiles (Fig. 1b). Candidate ligands focused on common chelators; chelation underpins successful retentive equilibria in living systems<sup>11</sup>. In an initial survey of ligands in model reactions, with a focus on multi-dentate N-, S- and O-type chelators (Supplementary Methods), *N,N,N,N*-tetramethylethylenediamine (TMEDA) showed most promise. Notably this ligand is also present in the air-stable Doyle precatalyst (TMEDA)Ni(*o*-tolyl)Cl<sup>57</sup> and is reminiscent of the alkyl-linked bis-amine also found in the natural product nickel-metallophore staphylopin<sup>62</sup> (Fig. 1a).

Thus, a flexible aryl-nickel reagent platform **1a–1e** (TMEDA)-Ni-Ar(Hal) could be readily obtained by simply mixing TMEDA with Ni(COD)<sub>2</sub> and the corresponding aryl halide bearing the desired aryl for protein conjugation; an observed reactivity of ArI > ArBr ≫ ArCl led us to focus on ArI precursors giving **1** rather than **2** (TMEDA)-Ni-Ar(Br). Importantly, these reagents displayed desired differential selectivity for different nucleophiles. Thus, chemoselective reaction of the NHS-ester moiety in **1e** with amine nucleophiles allowed ready diversification to **1f** and **1g** (bearing putative ‘tags’<sup>63</sup> for further protein reactions such as azide<sup>64</sup> and terminal olefin<sup>65</sup>) without disruption of the complex, prior to subsequent reaction via the nickel centre with thiol nucleophiles. Moreover, despite the noted<sup>57,66,67</sup> effect of the *ortho*-methyl substituent in increasing complex stability via reducing associative substitution at metal, the platform also allowed generation of phenylated variants **1a–1d**.




**Fig. 1 | Biomimetic design of a biocompatible ‘ligand-balanced’ protein arylation reagent platform for abiotic in-cell chemistry based on nickel organometallics.** **a**, Toxicity and cellular uptake of nickel are controlled and mediated, respectively, in nature<sup>31</sup> by N/O ligand systems such as natural product staphylopin<sup>62</sup> or in complexes such as Ni(II)(L-His)(2-methyl-2,4-thiazolidine-dicarboxylic acid [MeTzDCA])-Ni-[L-His] or [L-His]-Ni-[L-His]. These control nickel’s sequestration state by coordinating ‘hand over’ through flexible

coordination to intermediary proteins such as Nika, HypB or HypA<sup>31</sup> prior to use in biocatalysis that in some cases even exploits nickel-organometallic-mediated C-S bond formation<sup>27</sup>. **b**, Upper: this work—search for balanced ligands, including N/O, allows biomimetic control and modulation of both toxicity and transport. These reagents therefore ‘ligand balance’ toxicity + transport versus maintained reactivity. Lower: synthesis of optimally ‘ligand-balanced’ (TMEDA)-Ni-Ar(I) reagents.

### Nickel-mediated arylation allows in vitro protein conjugation

As an initial test of this putative ligand balance S-arylation system we gauged reactivity in in vitro protein modification. The globular protein PstS, a bacterial phosphate transporter<sup>68</sup>, has previously proven to be a good model of biocompatibility within which Cys178

has moderate accessibility and so is useful as a test site<sup>47</sup>. Strikingly, across the aryl-nickel platform **1a–1g** we observed rapid and efficient S-arylation at Cys178 using just 5 equiv. within just 10 min (Fig. 2a). Interestingly, reactivity for phenylated variants (**1a–1d**, >95%) appeared slightly greater than that for *o*-tolylated (**1f**, **1g**, >80%).



**Fig. 2 | Nickel-mediated arylation allows ready in vitro protein conjugation.**

**a**, Aryl scope of protein S-arylation. **b**, Protein scope of protein S-arylation. Reactions were performed with cysteine-containing proteins (15  $\mu$ M, 50  $\mu$ l) in Tris buffer (20 mM, NaCl 150 mM, pH 8.0) using TMEDA-Ni-Ar(X) (5 mM in H<sub>2</sub>O,

5 equiv., 0.75  $\mu$ l) at 25  $^{\circ}$ C for 10 min under an open atmosphere. Reactions were analysed by LC-MS, with conversions of modified protein estimated from peak integration of calibrated ion count relative to unmodified protein.

These promising efficiencies in a model protein were then tested in a variety of representative protein folds and functions (Fig. 2b): small  $\alpha$ -helical nuclear protein histone H3,  $\beta$ -helical pentapeptide repeat protein Np $\beta$ <sup>69</sup>,  $\beta$ -barrel green fluorescent protein GFP,

( $\alpha\beta$ )<sub>8</sub>-barrel glycosidase enzyme SS $\beta$ G and the single-chain ‘nanobody’, cross-reactive against human and murine VCAM, cabVCAM<sup>70</sup>, which also contains an internal disulfide. All showed good reactivity allowing effective modification (up to >95%). Furthermore, survey across diverse

sites within single protein histone H3 also supported broad reactivity with minimal effect of site location.

### Ligand-balanced reagents allow cellular protein reaction

Having demonstrated broad, efficient and rapid reactivity via nickel-mediated arylation with apparently excellent in vitro biomolecule compatibility, we next probed the intended design of ‘ligand balancing’ in the minimization of off-target reactivities (Fig. 3).

We first compared the cellular toxicities of ‘ligand-free’ nickel sources ( $\text{Ni}(\text{OAc})_2$  and  $\text{NiSO}_4$ ) with that of TMEDA-chelated aryl-nickel **1f** in mammalian cells. Chinese hamster ovary (CHO) cells were treated with vehicle or different nickel species at varied concentrations for 1 h (Fig. 3a). **1f** exhibited negligible cell death, even up to concentrations of 2 mM. By contrast, with the non-chelated nickel species  $\text{Ni}(\text{OAc})_2$  the viability of CHO cells was decreased at concentrations as low as 0.1 mM. Notably, the critical role of ligand was confirmed by (TMEDA)  $\text{Ni}(\text{OAc})_2$  which, similar to **1f**, showed reduced toxicity (Fig. 3a, left). Human (HeLa) cells were also tested; again, the non-chelated nickel species,  $\text{NiSO}_4$ , exhibited considerable toxicity. By contrast, the TMEDA-coordinated aryl-nickel reagent **1f** showed no apparent impact on cell viability (Fig. 3a, right).

These observations implied remarkable biocompatibility of the TMEDA-chelated ‘ligand-balanced’ aryl-nickel platform in biological systems. We first tested this potential through intracellular protein arylation of a dominantly expressed protein in living cells. Using aryl-nickel **1a** we extended the demonstrated in vitro reactivity with PstS–Cys178 to form PstS–CysPh178 (see above) to the corresponding reaction inside living prokaryotic cells. Thus, upon incubation of **1a** with *Escherichia coli* BL21(DE3) bacteria overexpressing intracellular PstS–Cys178 at 15 °C for 3 h (followed by thorough washing to remove all **1a**, PBS buffer replacement  $\times 3$ , prior to lysis) we observed intracellular conversion of up to 40% PstS–CysPh178 (Fig. 3b and Supplementary Information). The generality of this reagent class for in-cell chemistry was further supported by the apparently broad ability of different reagents **1a**, **1d** and **1f** to also modify endogenous proteins in living *E. coli* (Extended Data Fig. 7).

Next, we tested arylation in living eukaryotic cells. Use of aryl-nickel reagent **1f** allowed the potential introduction of azide as a reporter ‘tag’ group into proteins. Using a 60-min pulse of **1f**, CHO cells were treated with no apparent toxicity (Fig. 3c). These treated cells were then probed in two ways. First, cell lysates were subjected to Cu(I)-catalysed azide–alkyne cycloaddition (CuAAC) with alkyne-(EG)<sub>4</sub>-biotin-labelling reagent **L1** (Fig. 3c). Western blot analysis presented an unambiguous concentration-dependent labelling pattern (Fig. 3d and Extended Data Fig. 1b), consistent with the widespread abundance of free Cys in the CHO proteome<sup>71,72</sup>. Second, CHO cells that had been pulsed with **1f** to drive intracellular arylation were also probed through fluorescence microscopy. After fixation and permeabilization, these were instead subjected to CuAAC ligation with alkyne-Cy5 labelling reagent **L2**. A specific fluorescent signal with intensity proportional to the concentration of **1f** again revealed a clear, non-saturated, dose response (Fig. 3e and Extended Data Fig. 1a, c–e):

transcellular staining was seen not only in the cytoplasm but also in the nucleus (Extended Data Fig. 1c–e). Together these results confirmed the intracellular efficacy of aryl-nickel-mediated chemical arylation, here in eukaryotes.

### Nickel-mediated arylation allows deep cell cysteinome profiles

The seeming breadth of cellular access and diversity of proteome labelling observed for the aryl-nickel-mediated arylation with reduced toxicity, coupled with its observed efficiency and speed, suggested its utility as a powerful (and potentially widescale) method for organometallic C–S bond formation in cells. Pioneering cysteine profiling<sup>40</sup> has to date proved largely effective in cellular lysates<sup>71,73–80</sup>, but has been more restricted in its extension to living cells<sup>81–84</sup> (Supplementary Note 1 and Supplementary Table 1).

To assess potential, live human embryonic kidney (HEK293T) cells were treated with **1f** for 1.5 h, with a control group treated only with dimethylsulfoxide (DMSO), and then dually analysed both for (1) site of arylation and (2) protein identity<sup>85,86</sup>. Thus, arylated organometallic-treated cells were lysed and reacted with a photocleavable biotin-alkyne reagent **L3** via CuAAC ligation, followed by capture on neutravidin-bearing beads. Enriched proteins resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and mass spectrometry (MS) analyses confirmed successful isolation (**ED**, Fig. 2a–c); **1f**-labelled samples exhibited a diverse repertoire of proteins, consistent with our observations made by fluorescence labelling (see above), while omission of **1f** labelling yielded minimal background signal. Following on-bead digestion with trypsin, the remaining **1f**-labelled peptides trapped on neutravidin-bearing beads were then released by ultraviolet (UV) irradiation, desalted and analysed by liquid chromatography–tandem mass spectrometry (LC–MS/MS) for site mapping (Fig. 4a).

Using an open search method<sup>87,88</sup>, the distribution of deviation from expected unmodified native peptide ( $\Delta m$ ) revealed a peak ( $\Delta m_{\text{exp}} = 257.1272$  Da, Fig. 4b) consistent with the expected arylation driven by **1f** as essentially the only modification, alongside a very minor peak indicative of the oxidation of arylated peptides ( $\Delta m_{\text{ox}} = 273.1222$  Da, Fig. 4b). This confirmed the designed mode of arylation as essentially the exclusive induced reaction. Next, a  $\Delta m_{\text{exp}}$  offset-directed search<sup>88</sup> was used to probe the chemoselectivity of arylation. This revealed a very high Cys selectivity for **1f** of >90% to >98% (Fig. 4c and Extended Data Fig. 2d; see also Extended Data Fig. 10 and Supplementary Note 2 for an extended discussion of this estimate). Moreover, an analysis of the oxidation-state dependency of this selectivity indicated reactivity associated only with free Cys and not with either disulfide or other oxidized (sulfenic, sulfinic or sulfonic; Extended Data Fig. 6) forms. Indeed, we observed no clear evidence for arylation of any other functional group in any of our experiments.


Notably, in all of these experiments highly consistent results were obtained in triplicate, revealing excellent reactive fidelity, and, in a single run when combined with nano-liquid chromatography two-dimensional fractionation<sup>89</sup>, strikingly revealed 10,982 cysteines that were modified by **1f**, originating from 4,963 proteins, markedly

### Fig. 3 | Biocompatible ligand-balanced reagent platform allows ready cellular protein conjugation.

TMEDA-coordinated aryl-nickel species are biocompatible and efficient cell labelling reagents. **a**, The viability of CHO cells was evaluated after incubation with various nickel sources at different concentrations for 1 h. Cell viability was assessed through counting of cells treated with WST-8 reagent<sup>90</sup>. The absorbance at 460 nm was measured and normalized to vehicle-treated cells. Error bars represent the s.d. from  $n = 5$  (left) or  $n = 4$  (right) independent biological replicates (see Supplementary Table 2 for exact  $P$  values). \*\*\*\* $P < 0.0001$ , \*\*\* $P < 0.001$ , \*\* $P < 0.01$ , \* $P < 0.05$ , NS, not significant (two-way ANOVA). **b**, Aryl-nickel complex **1a** was tested for intracellular modification of Cys178 in PstS–Cys178 protein overexpressed within *E. coli* cells. In the schematic, squares represent proteins in intracellular proteome. **c**, Schematic showing cell

labelling, either by western blot analysis or confocal fluorescence imaging.

**d**, Immunoblot analysis of biotinylation confirmed that the labelling intensity is concentration dependent for **1f** probe followed by reaction with biotin-labelling reagent **L1** using CuAAC.  $\beta$ -Actin demonstrates equal loading. A representative western blot from  $n = 3$  independent experiments with similar results is shown. **e**, Upper: detection of proteome labelling in CHO cells by fluorescence confocal microscopy. **1f**-‘tagged’ proteins bearing azide following intracellular arylation were then labelled with alkyne-Cy5 dye **L2** using CuAAC (red). Hoechst 33342 was used to label nuclei of cells (blue). Scale bars, 40  $\mu\text{m}$ . Lower: the error bars represent the s.d. from  $n = 9$  independent replicates. For further representative images see Extended Data Fig. 1a, c, d, e.



outstripping by 3-fold (even in unoptimized form and with a focus on non-membrane targets) current reagents<sup>34</sup>. Comparison with the combined set of all previous in-cell Cys profiling data revealed an essential doubling of the Cys-bearing proteins that may now be targeted covalently in living cells enabled by the method (Fig. 4d).

### Organometallic C–S-arylation extends whole-cell profiling

This profile of in-cell organometallic C–S-bond-forming reactivity was analysed in further depth. Even when compared to the combined 19-dataset collection of all previous Cys profiling (in lysates and in cells; Extended Data Fig. 4e,f and Supplementary Table 1), including those that have been described as ‘high coverage’<sup>77</sup> lysate data, >40% of observed cysteines were novel (4,439, found on 2,156 proteins; Extended Data Fig. 4e,f). Moreover, of the 4,963 proteins that underwent covalent in-cell reaction with **1f**, 83% are classified as ‘non-ligandable’ (non-targetable by current drugs or probes) according to the DrugBank database ([www.drugbank.ca](http://www.drugbank.ca), Fig. 4e).

Notably, this in-cell reactivity appeared to bear no strong underlying biases. Although there was some observed distribution (21.7%) towards more exposed residues (pPSE  $\leq 2$ , using the AlphaFold-enabled ‘prediction-aware part-sphere exposure’ (pPSE) score<sup>90</sup> as one measure of accessibility), buried residues ( $5 < \text{pPSE} < 13$ ) also accounted for approximately 50% of **1f**-labelled cysteines. Associated enrichments of no more than  $\pm 2\%$  against average Cys distribution were also modest compared to other reagents (Fig. 4f), again indicating little to no bias. Furthermore, the accessibility distribution pattern of individual residues found in labelled peptides (Extended Data Fig. 3e) aligned with reported patterns for all human proteins<sup>72</sup>. No clear peptide sequence or motif-specific reactivity was observed either (Extended Data Fig. 3d).

Biochemical and possible ontological function were also assessed (Fig. 4g and Extended Data Fig. 4a–d). No global biases towards proteins with either active (Extended Data Fig. 4a,g,h) or binding (Extended Data Fig. 4b) sites were seen. This suggested that although, for example, some Cys catalytic nucleophiles in active sites were trapped, this was not strongly driving globally dominant chemistries, accounting for only a small fraction of those with nucleophiles in total (Extended Data Fig. 4a). Among the 4,352 proteins identified by **1f** that have high-confidence structural predictions<sup>91</sup>, 414 proteins contain annotated active sites. We evaluated the minimum Euclidean distance between **1f**-labelled cysteines and these active sites; these also suggested a low bias (Extended Data Fig. 4g). Sites included not only residues within active sites but also adjacent (Extended Data Fig. 4h); this suggests utility in modulating protein function not only via catalytic residue trapping but also via first- and second-sphere sites<sup>92–94</sup> and through display of fragments at the ‘rim’ of active sites (see also ‘Discussion’)<sup>95,96</sup>.

Equally, there appeared to be little global biasing towards metal binding sites, including, for example, zinc-finger sites (which might be expected to have a suitable architecture for first-row transition metals if ‘free’), consistent with our design of a ligand-balanced system that would prevent unwanted sequestering. Interestingly, of the sites

susceptible to mutagenesis (as identified by Uniprot), **1f** displayed a capability to trap those sites bearing Cys, but again in a seemingly non-biased manner (Extended Data Fig. 4d). Once again, in these subsets, accessibility distributions appeared essentially globally unbiased (Fig. 4g).

Intriguingly, Gene Ontology (GO) analyses of these **1f**-modified proteins (using DAVID<sup>97,98</sup>) indicated that there were apparently significant enrichments in RNA-binding and protein-binding function (Extended Data Fig. 3a) and in associated biological processes, including cell division, DNA repair and chromatin remodelling (Extended Data Fig. 3b). Notably, the identified proteins spanned a range of cellular locations and organelles, underscoring not only the cell-penetrating ability of reagents but also their seemingly wide distribution therein (Extended Data Fig. 3c).


Cysteine can often be sensitive to redox regulation inside a living cell, the homeostasis of which is probably lost in the lysate-only analyses. Although a detailed analysis of all  $\sim 10,500$  Cys that we identified is beyond the scope of this work (and would be required to establish full significance), several of the examples of the targeted Cys residues are also ones with experimentally verified redox-modulation roles. These included: Cys13 of cytosolic low-molecular-weight protein tyrosine phosphatase Acpl (UniProt P24666); Cys152 of GAPDH (UniProt P04406)<sup>99</sup>; Cys129 of the linear deubiquitinase Otulin (UniProt Q96BNS)<sup>100</sup>; Cys340 in the redox-regulated dynamic catalytic loop of the mitochondrial succinate-semialdehyde dehydrogenase Ssadh (UniProt P51649)<sup>101</sup>; and strikingly both Cys43 and Cys46 of the redox shuttle system in the cytosolic disulfide-reductase/peroxidase thioredoxin domain-containing protein Txndc17/Trp14 (UniProt Q9BRA2)<sup>102</sup>. Together these examples, along with our observations made on the apparent selectivity for Cys in its reduced state (see above), suggested strong proof-of-principle of the ligand-balanced organometallic system we describe here to trap relevant protein redox states inside living cells.


Next, we chose to probe the limits of sensitivity of arylation system in its ability to retrieve and identify proteins from living cells (Fig. 5). Data-independent acquisition (DIA) methods<sup>103</sup> provide a current benchmark for the survey of protein contents. We compared signal intensity of detected peptides derived from the use of **1f** to DIA assessment of protein abundance within the cell (Fig. 5a). Highly abundant cytoplasmic proteins, such as heat shock protein HSP90 (HSP90AB1) or translation elongation factor 2 (EEF2), were readily identified as expected. Notably, this detection was enabled by diverse peptides varying in intensity values across >4 orders of magnitude (Fig. 5a, red lines). Consistent with the broad reactive accessibility of our ligand-balanced organonickels (see above), these reflected both more-and-less accessible sites in proteins (for example, sites 23, 204 and 212 from cytoplasmic ubiquitin thioesterase OTUB1). Excitingly, this wide (>4-order) dynamic range of detection was reflected in much less-abundant proteins also. Thus, even at abundances approximately three orders of magnitude lower, we could map diverse peptides of both transcriptional corepressor TLE4 chromokinesin and Kif4A, a protein involved in chromatin segregation during mitosis (both predominantly present

### Fig. 4 | Live-cell cysteino profiling with ligand-balanced aryl-nickel **1f**.

**a**, Workflow of the dual analysis for proteomic mapping of both proteins and modification sites by **1f**. **1f** was typically used at 1 mM for 1.5 h. **b**, Assigning the masses of modification that occur proteome-wide by FragPipe’s Open Search. The peaks highlighted in red are the expected modifications ( $\Delta m_{\text{exp}}$ ) resulting from arylation of **1f**. Further modification of the arylated peptides by oxidation ( $\Delta m_{\text{ox}}$ ) was also detected. PSMs, peptide spectrum matches. **c**, Percentage of unique **1f** modified amino acids based on type of nucleophilic amino acids. FragPipe’s offset search was used for localizing this modification to the modified amino acid(s). It should be noted that precise localization in LC–MS/MS data is not possible for nearly all peptides/spectra because the data is rarely complete and this represents a conservative estimate (see Supplementary Note 2 for further discussion). Therefore, there is no statistical robustness to ‘additional’ residues shown here,

and comparable analyses (Extended Data Fig. 10) yield estimated selectivities of up to >98% (for example, based on the use of  $\geq 2$  precursors). We observe no validated data for residues other than Cys being modified. **d**, Venn diagrams showing the overlap between combined existing in-cell profiling datasets (black) and discovered cysteine sites (top) and protein targets (bottom) obtained here with **1f** (red). **e**, Classification of cysteines uniquely labelled by **1f** based on parent protein ligandability from the DrugBank database. **f**, Accessibility distributions of **1f**-labelled cysteine residues compared to the whole-proteome average distributions. Low-confidence predictions (AlphaFold2 prediction quality <70) were removed. Colours denote percentage change of each pPSE over the whole proteome average. **g**, Accessibility distributions of **1f**-labelled cysteine annotated with specific functions in UniProtKB. Low-confidence predictions (AlphaFold2 prediction quality <70) were removed.





**Fig. 5 | The dynamic range of 1f-labelling and its capability in labelling low-abundance proteins. a**, Scatter plot of intensity values of peptides from 1f-labelled proteins via in-cell chemistry versus abundance of proteins determined via DIA of HEK293T whole-cell lysate (WCL). Each point represents 1f-labelled peptide mapped against protein intensity value. Selected proteins illustrate (in red), wide dynamic range varying over both high- and low-abundance proteins. In total, 1,665 proteins identified with 1f were not found in the DIA survey, suggesting an ability to label even lower abundance. **b**, Protein ranking


comparison; 1f-identified proteins are shown as red points. Proteins are ranked based on measured intensity values from a deep-coverage HEK293T protein dataset covering >8,000 proteins and sorted in ascending order. Select labels reveal a marked ability to capture even the lowest-abundance proteins from diverse cellular locations (see text). **c, d**, Annotated spectra from the detection of viral proteins in human cells: detection of SV40 (**c**), and detection of splice variant products of Ad5 E1b (left, E1b19k; middle and right, E1b55k) (**d**). PEP, posterior error probability.

in the nucleus) across a similarly broad dynamic range of intensities (Fig. 5a, red lines). Even lower abundance biomarker proteins could be observed, detected with similarly broad dynamic range also, including MAP4, one of the suggested modulators of paclitaxel sensitivity<sup>104,105</sup>.

We assessed the lower limits of this seemingly highly sensitive method. Comparison (Fig. 5a) had revealed that >1,600 lower-abundance proteins not identified through DIA methods could be identified using 1f. To sample these further we therefore utilized a deep coverage HEK293T protein abundance dataset<sup>106</sup> ranking >8,000 of the most abundant (Fig. 5b). Although not all proteins were mapped, even within this depth it proved possible to identify the lowest-abundance proteins. Consistent with their functions, some of these are found at only very low copy numbers: the protein kinase MARK2 that is involved in determining cell polarity<sup>107</sup>, the MAP kinase

MAP3K15 that is a suggested but currently unaddressed target for diabetes<sup>108</sup> and CDC42-guanine nucleotide exchange factor MCF2L, a low-level proposed biomarker in atherosclerotic plaques<sup>109</sup> that is also correlated with poor prognosis in renal cancer<sup>110</sup> and for which there is also no current reliable method of measurement.

Finally, there is perhaps no greater test of the ability to survey a given cell's contents than the detection of foreign proteins, such as those derived, for example, from exogenous pathogens. Not only did the use of 1f to survey the cellular contents of human cell HEK293T allow the detection of the major T-antigen protein of simian virus SV40, a very low-level transcription factor derived from SV (Fig. 5c), but even splice variant isoforms of envelope protein E1b (E1b55k, P03243 and E1b19k, P03246; Fig. 5d) that arise from human adenovirus C serotype 5 (so-called Ad5) were detected.



**Fig. 6 | Pathogen trapping with ligand-balanced aryl-nickel 1f.** **a**, Schematic of *C. trachomatis* infection cycle in HEK293 cells and stage-specific cysteine site identification by 1f. HEK293 cells were infected at MOI < 0.1 and pulsed with 1f at 3, 8 and 24 hpi (see also Extended Data Fig. 9). Labelled cysteines were identified by MS/MS, and sites associated with RB–EB transitional stages are shown.

**b**, Scatter plot comparing protein intensities in WCL versus 1f-labelled proteins at 24 hpi. *C. trachomatis* proteins harbouring 1f-labelled cysteine sites (**a**) are highlighted in red. **c**, Schematic of SINV infection development in HEK293 cells and critical cysteine identification by 1f. After entry and membrane fusion, the

genomic RNA is first translated to produce non-structural proteins (nsP1–nsP4), which mediate RNA replication and subgenomic RNA synthesis. Structural proteins (C, E2, 6K, E1) are then translated from the subgenomic RNA. 1f labelling revealed arylation of C723 in nsP2 and C288 in nsP3. The structural context for each cysteine is illustrated. **d**, Scatter plots of protein intensities in WCL versus 1f-labelled proteins at 8 hpi (top) and 18 hpi (bottom). Viral proteins are highlighted in red. **e**, Time-course intensities of SINV structural and non-structural proteins in WCL. Error bars represent the s.d. from  $n = 3$  independent replicates. **f**, Intensity comparison of nsP2-C723 and nsP3-C288 labelling at 8 and 18 hpi.

### In-cell tracking of pathogen infection and target sites

Excitingly, these methods had shown promise even for the observation of proteins within a cell that are foreign to a given species genome. The detection of SV40 and Ad5 proteins (including splice variants)

suggested the potential to detect even the gene products that arise downstream of pathogenic (viral) infection. Ad5 genomic integration into HEK293 that has been observed by previous sequencing<sup>111</sup> and transcript analyses is thought to be a consequence of its ethically

inglorious origins as a cell line<sup>112</sup>. Dual detection of alternatively spliced viral protein products appears to be unprecedented, possibly due to their complex, dynamic expression and very low abundance<sup>113</sup>. Our results therefore suggested that the in-cell chemistries we reveal here may not only allow detection of endogenous human genome biomarkers (see above) but even those of emerging pathogens.

To robustly test such intracellular methods, we next chose pathogens—bacterial and viral—that necessarily require intracellular activity for emerging protein function (Fig. 6). *Chlamydia trachomatis* is an obligate intracellular bacterial pathogen that causes sexually transmitted infections and trachoma worldwide<sup>114–116</sup>, and has proven essentially refractory to traditional modes of genetic manipulation<sup>117</sup>. *Chlamydia*'s biphasic life cycle is thought to involve transitioning inside of host cells between the infectious, non-replicative elementary body (EB) that is first taken up and a replicative, non-infectious reticulate body (RB) that emerges inside the cell (Fig. 6a)—this also makes it, and the associated emerging protein functions, challenging to study<sup>118,119</sup>. Alphaviruses are small, enveloped RNA viruses that infect humans, causing fever, skin rash, arthralgia and even death<sup>120,121</sup>. Of these Sindbis (SINV) is as an old-world alphavirus archetype for studying the intriguing and emerging virus–host interactions and replication mechanisms that hijack and disrupt host machinery, many of which are thought to involve multifunctional and scarce ‘non-structural’ proteins that emerge post-infection (Fig. 6c) as well as more abundant structural proteins. It is also closely related to chikungunya virus (CHIKV), a pathogen of concern as designated by the World Health Organization with increasing incidence across the globe due to the expansion of its mosquito vectors.

In both cases, HEK293 cells were infected with *C. trachomatis* or SINV at low multiplicities of infection (MOIs) (down to <0.1 to mimic physiological conditions and test the sensitivity for emerging proteins) and pulse-labelled with **1f** at different time points (see Fig. 6 and Extended Data Fig. 9 for workflow). Cells were lysed and subjected to our standard workflows. Western blot analyses revealed labelling across all **1f**-treated samples, with a signal decrease in the case of SINV-infected samples 8 h post-infection (hpi), suggestive of SINV-induced translational shut-off (Extended Data Fig. 9), thereby increasing the challenge of protein detection yet further.

In *C. trachomatis*-infected cells, we saw >500 emerging bacterial proteins (Fig. 6b). Amongst these we trapped nine specific Cys sites from eight bacterial proteins at 24 hpi. Notably, these included OmpA, the major outer membrane protein that classifies strains into serovars based on its polymorphism and is the main target of host immune response<sup>122,123</sup>. Moreover, we identified six proteins thought to be expressed only during the post-uptake, replicative RB state of *Chlamydia* and its further differentiation: Tig (RB)<sup>16</sup>, RplO, RplS and RplA (RB)<sup>124</sup>, Euo (the repressor for late gene transcription, before RB-to-EB)<sup>125,126</sup> and DksA (RB-to-EB)<sup>127</sup>. The latter, DksA, interestingly has been suggested as maximal just before the bacterial cycle ‘pinchpoint’ of further RB-to-EB differentiation through inclusion-forming unit analyses and electron microscopy<sup>127–129</sup>. The confirmation of the emergence of these proteins not only highlighted their key roles at this time point but also revealed the ability of our method to target proteins in a pathogen once it has undergone life-cycle-specific intracellular differentiation (here EB-to-RB and even then further RB-to-EB). Notably, these covalently targeted proteins included those considered to be essential and therefore putative antimicrobial targets: Tig is from a class of ribosome-associated bacterial chaperone that stabilizes nascent proteins<sup>130</sup>; RecA is central to bacterial homologous DNA repair and the bacterial SOS response<sup>131</sup>; and DksA, alongside Euo, critically regulate the chlamydial developmental cycle<sup>127</sup>. Bacteria-specific ribosomal proteins RplO, RplS, and RplA were also targeted—ontological analyses<sup>132</sup> suggest that alongside Tig these are likely to form a ribosomal cluster known to be critical for bacterial protein translation in other species<sup>130</sup>.

In SINV-infected cells, even with a more limited emergent proteome at relatively low MOI<sup>133</sup>, we were able to see a clearly developing viral proteome (Fig. 6e). From this we successfully trapped Cys sites in two key non-structural proteins (nsPs): Cys723 in nsP2 (SINV's critical dual helicase/protease), adjacent to Pro726 at a region known to reduce viral RNA replication and to ablate cytopathic host transcriptional/translational shutdown; and Cys288 in nsP3, located at the heart of its conserved zinc-binding domain that is essential for viral replication<sup>134</sup>. Again, these covalently targeted protein sites represented putative antiviral targets essential to infective function that were modifiable by in-cell covalent arylation. Promisingly, Cys288 was targeted consistently in this Cys-rich cluster at an increasing level as infection progressed (Fig. 6f), suggestive of a ‘privileged’ residue.

Although the methods we disclose here are not intended to yet identify targets in the currently ‘undruggable’ proteome (see above and Extended Data Fig. 4), these pathogen surveys have already revealed intriguing putative sites for future exploration. Of the protein products identified as emerging in *Chlamydia*, the trigger factor Tig (arylated at Cys339) and the specific *Chlamydia* translational machinery proteins from both the small (RpsA at Cys20) and large (RplO at Cys75, RplS at Cys21) subunits of its ribosome suggest putative conserved Cys that could be investigated. Moreover, in SINV, the arylation of two critical non-structural proteins nsP2 and nsP3 that are part of the vRNA replicase complex<sup>135</sup> and so critical for replication is also suggestive. Cys723 in nsP2 is located next to Pro726, a well-characterized non-cytopathic mutation<sup>136,137</sup> that reduces viral RNA replication and prevents host transcriptional and translational shut-off<sup>138–140</sup>. In particular, the consistent arylation over time of just Cys288 in the central zinc-binding domain of nsP3 (a protein that is conserved across all alphaviruses) despite the presence of several other Cys in that domain suggests an ‘activated’ site. Mutations in this domain in nsP3 critically prevent non-structural polyprotein expression and viral replication<sup>134,137,141</sup>—this was arylated as early as 8 hpi, implicating potentially early intervention. This is perhaps the first example of transition metal-based direct targeting of a putatively critical pathogen protein in living cells.

## Discussion

Here we have described TMEDA-coordinated aryl-nickel reagents for site-selective protein S-arylation that, through ‘ligand balancing’, appear to be usefully biocompatible. Their ready and rapid use to create robust C–S bonds not only within proteins *in vitro* but also for live cell labelling markedly expands the application of metal-based reagents in biology.

For this thiol-targeting chemistry to succeed inside the living cell, high reactivity, reaction rate and cellular penetration all need to combine to trap even low-abundance thiols (for example, those found on low copy number proteins). Four known in-cell datasets have covered ~13,400 unique Cys in combined total over ~10 years<sup>81–84</sup>; here, we have essentially doubled both Cys site and protein coverage with a single reagent (Extended Data Fig. 4e,f). We attribute the success of our method, in part, to the ability to now exploit organometallic reagents but also to the concentration of these reagents that cells appear to tolerate (here millimolar when previous reagents<sup>81–84,142</sup> have been restricted to ~200  $\mu\text{M}$  or less)—both are a consequence of the design of these ‘ligand-balanced’ (reduced-toxicity plus reactivity) organonickels. This is further supported by an ability to extend treatment times with **1f** (even to 3 h with 1 mM **1f** in HeLa; Extended Data Fig. 8a) and by assessment of putative cellular stress markers (Extended Data Fig. 8d and Supplementary Methods) and comparison with one of the most currently widely used Cys-modification reagents: ‘iodoacetamide-alkyne’, IAA (see Extended Data Fig. 5 and Supplementary Methods).

It should be noted that the measured<sup>4</sup> toxicity thresholds for other synthetically-powerful metal (for example, palladium)-mediated chemistries, have not prevented their use in modification of proteins in prokaryotic cells. For example, the Suzuki–Miyaura reaction, mediated

by preformed palladium–pyrimidine complexes, can be used to target iodo-Phe, introduced through stop-codon suppression, in *E. coli*<sup>4,5</sup>. Homo-propargylglycine (Hpg), introduced to the C terminus of ubiquitin in Met-auxotrophic *E. coli* cells, can be addressed with similar complexes allowing palladium-mediated Sonogashira reactions<sup>143</sup>. Lysyl propargyl carbamates or iodo-benzyl carbamates introduced through stop-codon suppression in *E. coli*, *Shigella* and *Salmonella* bacteria are also successfully targeted by these palladium complexes<sup>14</sup>. Their further potential, however, in more complex cellular systems is, as yet, undisclosed. Our initial experiments here suggest that palladium complexes show greater toxicity than Ni (at >0.2 mM in HEK293T; Extended Data Fig. 8b) but that, as we find here, this may be partially mitigated by ligand alteration.

The reduced-toxicity usage within both prokaryotic and eukaryotic cells that we now show here suggests that nickel organometallics—with the correct ligand system—may prove particularly useful for some intracellular reactions, such as C–S-bond-forming arylation with apparently much broader cellular scope. It is noteworthy that, paralleling these results, nickel is often successfully localized and transported into and within living systems, seemingly without unwanted side-sequestration, through the implicated use of N-type ligands<sup>31</sup>. For example, the N-terminal domain residue His2 imidazole side chain is critical in HypB- to HypA-mediated nickel transfer in helper proteins that control directional metal transfer<sup>30</sup>. Moreover, subtle variation of N,N-type systems has allowed selective (for example *o*-phenanthroline over neocuprine)<sup>28</sup> nickel chelation in biocatalytic systems. Together, such observations reinforce a premise that certain modes of native metal usage might usefully guide future design of other metal-mediated chemistry in living systems.

Amongst its features, nickel is a first-row transition metal with a geometry that is typically ligand dependent; in resting square-planar geometries putative axial sites utilized for associative steps can also be partially protected or modulated by ligands. This may usefully determine, as we show here, the ability to ‘ligand balance’. It may also be that, in this context, the ability of metals to not only differently equilibrate between alternative coordination geometries but also even exploit different ligand environments in biomolecule targets could add another aspect of selectivity in their future use. It should be noted therefore that the precise arylating species that is functional in the current work may therefore arise *in situ*. Again, future studies on how nature transports nickel to active sites might serve to inform not only such chemical selectivity in biology but also even the design of metal binding sites in *de novo* biometallocalysts. The added ability to access reaction manifolds and corresponding redox potentials that nature will not have accessed creates alternative reaction pathways and therefore useful orthogonal selectivities<sup>1</sup>.

Indeed, the existing selectivities (for example, S over N) that we observe are already powerful. Reagent **1e** is an intriguing *bis*-electrophile in that its diversification and then protein reaction is enabled by N-selective reaction at activated carboxyl first followed by S-selective association and then reaction at Ni<sup>0</sup>. In cells **1f** shows striking apparent S-selectivity that parallels these observations and that outstrips  $\alpha$ -iodocarbonyls, perhaps unsurprisingly given the long known reactivity of  $\alpha$ -iodocarbonyls with other protein residues (for example, His)<sup>39</sup>. It may therefore even prove possible in the future to use such (or similar) reagents for modes of (for example, N- plus S-selective with **1e**) cross-linking<sup>144</sup> or stapling<sup>145</sup> in living systems based on the initial biocompatibility that we show here. The ability to install diversely modified aryls into protein side chains highlights also the potential for creation of potential mimics of aromatic amino acids and their post-translationally modified forms, as has been elegantly explored by other methods *in vitro*<sup>146,147</sup>.

Current modes of cellular characterization and dynamics still rest primarily on genetic analyses<sup>148</sup>. Although the function of biology is mediated at the post-translational level, we have yet to develop in-cell

chemistries that could allow sufficiently sensitive mapping to enable the routine profiling of the deeper subtleties of cellular identity. In this sense, the curious pseudotriploidy<sup>149</sup> of HEK293T provides an additional test. It is therefore notable that (despite its name) HEK293 has been for two decades<sup>112</sup> considered a neuronal (probably adrenal) cell that was present in the fetal kidney tissue used for its generation. Our detection now, using new organometallic methods, of even the archetypal kidney-specific marker polycystin-2 PKD2 (at ultralow sub-log<sub>10</sub> 6 levels; Fig. 5b)—suggesting at least partial kidney cell characteristics—now moderates this notion and highlights the complexity of cellular characterization in dynamic proteomes. When also coupled with our tracking of emerging intracellular pathogens, which allow highly specific retrieval of serovar-specific proteins (such as OmpA in *Chlamydia*), it therefore suggests that ultrasensitive chemoproteomic methods based on new chemistries in living systems, as we reveal here, may provide additional future pathways to both cellular and pathogen (even when intracellular) characterization and to the cellular response to exogenous challenge.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41557-025-02017-1>.

## References

1. Giltrap, A. M., Yuan, Y. & Davis, B. G. Late-stage functionalization of living organisms: rethinking selectivity in biology. *Chem. Rev.* **124**, 889–928 (2024).
2. James, C. C., de Bruin, B. & Reek, J. N. H. Transition metal catalysis in living cells: progress, challenges, and novel supramolecular solutions. *Angew. Chem. Int. Ed.* **62**, e202306645 (2023).
3. Chalker, J. M., Wood, C. S. C. & Davis, B. G. A convenient catalyst for aqueous and protein Suzuki–Miyaura cross-coupling. *J. Am. Chem. Soc.* **131**, 16346–16347 (2009).
4. Spicer, C. D., Triemer, T. & Davis, B. G. Palladium-mediated cell-surface labeling. *J. Am. Chem. Soc.* **134**, 800–803 (2012).
5. Spicer, C. D. & Davis, B. G. Rewriting the bacterial glycocalyx via Suzuki–Miyaura cross-coupling. *Chem. Commun.* **49**, 2747–2749 (2013).
6. Isenegger, P. G. & Davis, B. G. Concepts of catalysis in site-selective protein modifications. *J. Am. Chem. Soc.* **141**, 8005–8013 (2019).
7. Li, J. & Chen, P. R. Moving Pd-mediated protein cross coupling to living systems. *ChemBioChem* **13**, 1728–1731 (2012).
8. Lozhkin, B. & Ward, T. R. Bioorthogonal strategies for the *in vivo* synthesis or release of drugs. *Bioorg. Med. Chem.* **45**, 116310 (2021).
9. Sathyan, A., Deng, L., Loman, T. & Palmans, A. R. A. Bioorthogonal catalysis in complex media: consequences of using polymeric scaffold materials on catalyst stability and activity. *Catal. Today* **418**, 114116 (2023).
10. Crans, D. C. & Kostenkova, K. Open questions on the biological roles of first-row transition metals. *Commun. Chem.* **3**, 104 (2020).
11. Sears, M. E. Chelation: harnessing and enhancing heavy metal detoxification—a review. *Scientific World Journal* **2013**, 219840 (2013).
12. Willwacher, J., Raj, R., Mohammed, S. & Davis, B. G. Selective metal-site-guided arylation of proteins. *J. Am. Chem. Soc.* **138**, 8678–8681 (2016).
13. Dumas, A. et al. Self-liganded Suzuki–Miyaura coupling for site-selective protein PEGylation. *Angew. Chem. Int. Ed.* **52**, 3916–3921 (2013).

14. Li, J. et al. Ligand-free palladium-mediated site-specific protein labeling inside Gram-negative bacterial pathogens. *J. Am. Chem. Soc.* **135**, 7330–7338 (2013).
15. Tsubokura, K. et al. In vivo gold complex catalysis within live mice. *Angew. Chem. Int. Ed.* **56**, 3579–3584 (2017).
16. Yusop, R. M., Unciti-Broceta, A., Johansson, E. M. V., Sánchez-Martín, R. M. & Bradley, M. Palladium-mediated intracellular chemistry. *Nat. Chem.* **3**, 239–243 (2011).
17. Unciti-Broceta, A., Johansson, E. M. V., Yusop, R. M., Sánchez-Martín, R. M. & Bradley, M. Synthesis of polystyrene microspheres and functionalization with PdO nanoparticles to perform bioorthogonal organometallic chemistry in living cells. *Nat. Protoc.* **7**, 1207–1218 (2012).
18. Miller, M. A. et al. Nano-palladium is a cellular catalyst for in vivo chemistry. *Nat. Commun.* **8**, 15906 (2017).
19. Wang, F. M., Zhang, Y., Du, Z., Ren, J. S. & Qu, X. G. Designed heterogeneous palladium catalysts for reversible light-controlled bioorthogonal catalysis in living cells. *Nat. Commun.* **9**, 1209 (2018).
20. Sancho-Albero, M. et al. Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis. *Nat. Catal.* **2**, 864–872 (2019).
21. Boer, J. L., Mulrooney, S. B. & Hausinger, R. P. Nickel-dependent metalloenzymes. *Arch. Biochem. Biophys.* **544**, 142–152 (2014).
22. Zamble, D. B. Nickel in biology. *Metallomics* **7**, 588–589 (2015).
23. Macomber, L. & Hausinger, R. P. Mechanisms of nickel toxicity in microorganisms. *Metallomics* **3**, 1153–1162 (2011).
24. Zambelli, B., Uversky, V. N. & Ciurli, S. Nickel impact on human health: an intrinsic disorder perspective. *Biochim. Biophys. Acta Proteins Proteom.* **1864**, 1714–1731 (2016).
25. Song, X., Fiati Kenston, S. S., Kong, L. & Zhao, J. Molecular mechanisms of nickel induced neurotoxicity and chemoprevention. *Toxicology* **392**, 47–54 (2017).
26. Šulinskienė, J. et al. Effect of zinc on the oxidative stress biomarkers in the brain of nickel-treated mice. *Oxid. Med. Cell. Longev.* **2019**, 8549727 (2019).
27. Can, M., Armstrong, F. A. & Ragsdale, S. W. Structure, function, and mechanism of the nickel metalloenzymes, CO dehydrogenase, and acetyl-CoA synthase. *Chem. Rev.* **114**, 4149–4174 (2014).
28. Seravalli, J. et al. Evidence that NiNi acetyl-CoA synthase is active and that the CuNi enzyme is not. *Biochemistry* **43**, 3944–3955 (2004).
29. Gregg, C. M., Goetzl, S., Jeoung, J.-H. & Dobbek, H. AcsF catalyzes the ATP-dependent insertion of nickel into the Ni<sub>2</sub>Ni-[4Fe4S] cluster of acetyl-CoA synthase. *J. Biol. Chem.* **291**, 18129–18138 (2016).
30. Lacasse, M. J., Douglas, C. D. & Zamble, D. B. Mechanism of selective nickel transfer from HypB to HypA, *Escherichia coli* [NiFe]-hydrogenase accessory proteins. *Biochemistry* **55**, 6821–6831 (2016).
31. Zeer-Wanklyn, C. J. & Zamble, D. B. Microbial nickel: cellular uptake and delivery to enzyme centers. *Curr. Opin. Chem. Biol.* **37**, 80–88 (2017).
32. Ongey, E. L. & Banerjee, A. In vitro reconstitution of transition metal transporters. *J. Biol. Chem.* **300**, 107589 (2024).
33. Pegg, A. E. Multifaceted roles of alkyltransferase and related proteins in DNA Repair, DNA damage, resistance to chemotherapy, and research tools. *Chem. Res. Toxicol.* **24**, 618–639 (2011).
34. Wang, M. & Casey, P. J. Protein prenylation: unique fats make their mark on biology. *Nat. Rev. Mol. Cell Biol.* **17**, 110–122 (2016).
35. Clarke, S. G. The ribosome: a hot spot for the identification of new types of protein methyltransferases. *J. Biol. Chem.* **293**, 10438–10446 (2018).
36. Chalker, J. M., Bernardes, G. J. L., Lin, Y. A. & Davis, B. G. Chemical modification of proteins at cysteine: opportunities in chemistry and biology. *Chem. Asian J.* **4**, 630–640 (2009).
37. Gunnoo, S. B. & Madder, A. Chemical protein modification through cysteine. *ChemBioChem* **17**, 529–553 (2016).
38. Wang, C. & Junfeng Zhao, Y. Z. Recent advances in chemical protein modification via cysteine. *Chin. J. Org. Chem.* **42**, 2774–2792 (2022).
39. Spicer, C. D. & Davis, B. G. Selective chemical protein modification. *Nat. Commun.* **5**, 4740 (2014).
40. Xiao, W., Chen, Y. & Wang, C. Quantitative chemoproteomic methods for reactive cysteinome profiling. *Isr. J. Chem.* **63**, e202200100 (2023).
41. Zhang, C., Vinogradova, E. V., Spokoyny, A. M., Buchwald, S. L. & Pentelute, B. L. Arylation chemistry for bioconjugation. *Angew. Chem. Int. Ed.* **58**, 4810–4839 (2019).
42. Zhang, C. et al. *π*-Clamp-mediated cysteine conjugation. *Nat. Chem.* **8**, 120–128 (2016).
43. Embaby, A. M., Schoffelen, S., Kofoed, C., Meldal, M. & Diness, F. Rational tuning of fluorobenzene probes for cysteine-selective protein modification. *Angew. Chem. Int. Ed.* **57**, 8022–8026 (2018).
44. Zhang, D., Devarie-Baez, N. O., Li, Q., Lancaster, J. R. Jr & Xian, M. Methylsulfonyl benzothiazole (MSBT): a selective protein thiol blocking reagent. *Org. Lett.* **14**, 3396–3399 (2012).
45. Toda, N., Asano, S. & Barbas, C. F. III. Rapid, stable, chemoselective labeling of thiols with Julia-Kocięński-like reagents: a serum-stable alternative to maleimide-based protein conjugation. *Angew. Chem. Int. Ed.* **125**, 12824–12828 (2013).
46. Brown, S. P. & Smith, A. B., III. Peptide/protein stapling and unstapling: introduction of S-tetrazine, photochemical release, and regeneration of the peptide/protein. *J. Am. Chem. Soc.* **137**, 4034–4037 (2015).
47. Fu, X.-P. et al. Stereoretentive post-translational protein editing. *ACS Central Sci.* **9**, 405–416 (2023).
48. Jbara, M. Transition metal catalyzed site-selective cysteine diversification of proteins. *Pure Appl. Chem.* **93**, 169–186 (2021).
49. Vinogradova, E. V., Zhang, C., Spokoyny, A. M., Pentelute, B. L. & Buchwald, S. L. Organometallic palladium reagents for cysteine bioconjugation. *Nature* **526**, 687–691 (2015).
50. Kung, K. K. et al. Cyclometalated gold(III) complexes for chemoselective cysteine modification via ligand controlled C–S bond-forming reductive elimination. *Chem Commun.* **50**, 11899–11902 (2014).
51. Messina, M. S. et al. Organometallic gold(III) reagents for cysteine arylation. *J. Am. Chem. Soc.* **140**, 7065–7069 (2018).
52. Bacauanu, V., Merz, Z. N., Hua, Z. L. & Lang, S. B. Nickel-catalyzed antibody bioconjugation. *J. Am. Chem. Soc.* **145**, 25842–25849 (2023).
53. Al-Shuaeeb, R. A. et al. Palladium-catalyzed chemoselective and biocompatible functionalization of cysteine-containing molecules at room temperature. *Chemistry* **22**, 11365–11370 (2016).
54. Zhao, W., Lee, H. G., Buchwald, S. L. & Hooker, J. M. Direct <sup>11</sup>CN-labeling of unprotected peptides via palladium-mediated sequential cross-coupling reactions. *J. Am. Chem. Soc.* **139**, 7152–7155 (2017).
55. Dhanjee, H. H. et al. Protein-protein cross-coupling via palladium-protein oxidative addition complexes from cysteine residues. *J. Am. Chem. Soc.* **142**, 9124–9129 (2020).
56. Rojas, A. J. et al. Divergent unprotected peptide macrocyclisation by palladium-mediated cysteine arylation. *Chem. Sci.* **8**, 4257–4263 (2017).
57. Shields, J. D., Gray, E. E. & Doyle, A. G. A modular, air-stable nickel precatalyst. *Org. Lett.* **17**, 2166–2169 (2015).

58. Boehm, P. et al. Mechanistic investigation of the nickel-catalyzed metathesis between aryl thioethers and aryl nitriles. *J. Am. Chem. Soc.* **144**, 13096–13108 (2022).
59. Vara, B. A. et al. Scalable thioarylation of unprotected peptides and biomolecules under Ni/photoredox catalysis. *Chem. Sci.* **9**, 336–344 (2018).
60. Hanaya, K. et al. Rapid nickel(ii)-promoted cysteine S-arylation with arylboronic acids. *Chem Commun.* **55**, 2841–2844 (2019).
61. Qin, L.-Z. et al. Visible-light-induced nickel-catalyzed selective S-arylation of peptides by exogenous-photosensitizer-free photocatalysis. *Cell Rep. Phys. Sci.* **4**, 101292 (2023).
62. Ghsssein, G. et al. Biosynthesis of a broad-spectrum nicotianamine-like metallophore in *Staphylococcus aureus*. *Science* **352**, 1105–1109 (2016).
63. Chalker, J. M., Bernardes, G. J. L. & Davis, B. G. A “tag-and-modify” approach to site-selective protein modification. *Acc. Chem. Res.* **44**, 730–741 (2011).
64. van Kasteren, S. I. et al. Expanding the diversity of chemical protein modification allows post-translational mimicry. *Nature* **446**, 1105–1109 (2007).
65. Floyd, N., Vijayakrishnan, B., Koeppe, J. R. & Davis, B. G. Thiol glycosylation of olefinic proteins: S-linked glycoconjugate synthesis. *Angew. Chem. Int. Ed.* **48**, 7798–7802 (2009).
66. Moss, J. R. & Shaw, B. L. Nuclear magnetic resonance studies on metal complexes. Part IV. Arylnickel(II)–dimethylphenylphosphine complexes. *J. Chem. Soc. A* <https://doi.org/10.1039/J19660001793> (1966).
67. Uchino, M. A., Yamamoto, A. & Ikeda, S. Preparation and properties of aryl(dipyridyl)nickel halide complexes. *J. Organomet. Chem.* **84**, 93–103 (1975).
68. Qi, Y., Kobayashi, Y. & Hulett, F. M. The pst operon of *Bacillus subtilis* has a phosphate-regulated promoter and is involved in phosphate transport but not in regulation of the pho regulon. *J. Bacteriol.* **179**, 2534–2539 (1997).
69. Vetting, M. W., Hegde, S. S., Hazleton, K. Z. & Blanchard, J. S. Structural characterization of the fusion of two pentapeptide repeat proteins, Np275 and Np276, from *Nostoc punctiforme*: resurrection of an ancestral protein. *Protein Sci.* **16**, 755–760 (2007).
70. Broisat, A. et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. *Circ. Res.* **110**, 927–937 (2012).
71. Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. *Nature* **468**, 790–795 (2010).
72. White, M. E. H., Gil, J. & Tate, E. W. Proteome-wide structural analysis identifies warhead- and coverage-specific biases in cysteine-focused chemoproteomics. *Cell Chem. Biol.* **30**, 828–838.e824 (2023).
73. Abegg, D. et al. Proteome-wide profiling of targets of cysteine reactive small molecules by using ethynyl benziodoxolone reagents. *Angew. Chem. Int. Ed.* **54**, 10852–10857 (2015).
74. Backus, K. M. et al. Proteome-wide covalent ligand discovery in native biological systems. *Nature* **534**, 570–574 (2016).
75. Ochtrop, P. & Hackenberger, C. P. R. Recent advances of thiol-selective bioconjugation reactions. *Curr. Opin. Chem. Biol.* **58**, 28–36 (2020).
76. Kuljanin, M. et al. Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries. *Nat. Biotechnol.* **39**, 630–641 (2021).
77. Yan, T. et al. SP3-FAIMS chemoproteomics for high-coverage profiling of the human cysteinome. *ChemBioChem* **22**, 1841–1851 (2021).
78. Darabedian, N. et al. Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor. *Nat. Chem. Biol.* **19**, 815–824 (2023).
79. Hartmann, P. et al. Chemoselective umpolung of thiols to episulfoniums for cysteine bioconjugation. *Nat. Chem.* **16**, 380–388 (2024).
80. Bao, G. et al. Orthogonal bioconjugation targeting cysteine-containing peptides and proteins using alkyl thianthrenium salts. *Nat. Commun.* **15**, 6909 (2024).
81. Abo, M. & Weerapana, E. A caged electrophilic probe for global analysis of cysteine reactivity in living cells. *J. Am. Chem. Soc.* **137**, 7087–7090 (2015).
82. Abo, M., Bak, D. W. & Weerapana, E. Optimization of caged electrophiles for improved monitoring of cysteine reactivity in living cells. *ChemBioChem* **18**, 81–84 (2017).
83. Motiwala, H. F., Kuo, Y. H., Stinger, B. L., Palfey, B. A. & Martin, B. R. Tunable heteroaromatic sulfones enhance in-cell cysteine profiling. *J. Am. Chem. Soc.* **142**, 1801–1810 (2020).
84. Liu, Y. et al. Oxidant-induced bioconjugation for protein labeling in live cells. *ACS Chem. Biol.* **18**, 112–122 (2023).
85. Speers, A. E. & Cravatt, B. F. A tandem orthogonal proteolysis strategy for high-content chemical proteomics. *J. Am. Chem. Soc.* **127**, 10018–10019 (2005).
86. Weerapana, E., Speers, A. E. & Cravatt, B. F. Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)—a general method for mapping sites of probe modification in proteomes. *Nat. Protoc.* **2**, 1414–1425 (2007).
87. Yu, F. et al. Identification of modified peptides using localization-aware open search. *Nat. Commun.* **11**, 4065 (2020).
88. Kong, A. T., Leprevost, F. V., Avtonomov, D. M., Mellacheruvu, D. & Nesvizhskii, A. I. MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. *Nat. Methods* **14**, 513–520 (2017).
89. Kitano, E. S. et al. Repurposed 3D printer allows economical and programmable fraction collection for proteomics of nanogram scale samples. *Anal. Chem.* **96**, 11439–11447 (2024).
90. Bludau, I. et al. The structural context of posttranslational modifications at a proteome-wide scale. *PLoS Biol.* **20**, e3001636 (2022).
91. Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583–589 (2021).
92. Cummins, I. et al. Unique regulation of the active site of the serine esterase S-formylglutathione hydrolase. *J. Mol. Biol.* **359**, 422–432 (2006).
93. Go, Y.-M., Chandler, J. D. & Jones, D. P. The cysteine proteome. *Free Radical Biol. Med.* **84**, 227–245 (2015).
94. Kim, H.-J., Ha, S., Lee, H. Y. & Lee, K.-J. ROSics: chemistry and proteomics of cysteine modifications in redox biology. *Mass Spectrom. Rev.* **34**, 184–208 (2015).
95. Erlanson, D. A. et al. Site-directed ligand discovery. *Proc. Natl Acad. Sci. USA* **97**, 9367–9372 (2000).
96. Erlanson, D. A. & Hansen, S. K. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. *Curr. Opin. Chem. Biol.* **8**, 399–406 (2004).
97. Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* **37**, 1–13 (2009).
98. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57 (2009).
99. Talwar, D. et al. The GAPDH redox switch safeguards reductive capacity and enables survival of stressed tumour cells. *Nat. Metab.* **5**, 660–676 (2023).
100. Snyder, N. A. & Silva, G. M. Deubiquitinating enzymes (DUBs): regulation, homeostasis, and oxidative stress response. *J. Biol. Chem.* **297**, 101077 (2021).
101. Kim, Y. G. et al. Redox-switch modulation of human SSADH by dynamic catalytic loop. *EMBO J.* **28**, 959–968–968 (2009).

102. Espinosa, B. & Arnér, E. S. J. Thioredoxin-related protein of 14 kDa as a modulator of redox signalling pathways. *Br. J. Pharmacol.* **176**, 544–553 (2019).
103. Law, K. P. & Lim, Y. P. Recent advances in mass spectrometry: data independent analysis and hyper reaction monitoring. *Expert Rev. Proteomics* **10**, 551–566 (2013).
104. Zhang, C. C. et al. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. *Oncogene* **16**, 1617–1624 (1998).
105. Yang, H. et al. Paclitaxel sensitivity of ovarian cancer can be enhanced by knocking down pairs of kinases that regulate MAP4 phosphorylation and microtubule stability. *Clin. Cancer Res.* **24**, 5072–5084 (2018).
106. Chen, H. et al. Omics analyses uncover host networks defining virus-permissive and -hostile cellular states. *Molecular Cellular Proteomics* **24**, 100966 (2025).
107. Wu, Y. & Griffin, E. E. in *Current Topics in Developmental Biology* Vol. 123 (ed Jenny, A.) 365–397 (Academic Press, 2017).
108. Nag, A. et al. Human genetics uncovers MAP3K15 as an obesity-independent therapeutic target for diabetes. *Sci. Adv.* **8**, eadd5430 (2022).
109. Maiwald, S. et al. A rare variant in MCF2L identified using exclusion linkage in a pedigree with premature atherosclerosis. *Eur. J. Hum. Genet.* **24**, 86–91 (2016).
110. The Human Protein Atlas. MCF2L (ENSG00000126217) <https://www.proteinatlas.org/ENSG00000126217-MCF2L> (accessed 28 November 2025).
111. Louis, N., Eveleigh, C. & Graham, F. L. Cloning and sequencing of the cellular–viral junctions from the human adenovirus type 5 transformed 293 cell line. *Virology* **233**, 423–429 (1997).
112. Shaw, G., Morse, S., Ararat, M. & Graham, F. L. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. *FASEB J.* **16**, 869–871 (2002).
113. Donovan-Banfield, I. A., Turnell, A. S., Hiscox, J. A., Leppard, K. N. & Matthews, D. A. Deep splicing plasticity of the human adenovirus type 5 transcriptome drives virus evolution. *Commun. Biol.* **3**, 124 (2020).
114. Elwell, C., Mirrashidi, K. & Engel, J. *Chlamydia* cell biology and pathogenesis. *Nat. Rev. Microbiol.* **14**, 385–400 (2016).
115. O’Connell, C. M. & Ferone, M. E. *Chlamydia trachomatis* genital infections. *Microb Cell* **3**, 390–403 (2016).
116. Taylor, H. R., Burton, M. J., Haddad, D., West, S. & Wright, H. Trachoma. *Lancet* **384**, 2142–2152 (2014).
117. Wan, W., Li, D., Li, D. & Jiao, J. Advances in genetic manipulation of *Chlamydia trachomatis*. *Front. Immunol.* **14**, 1209879 (2023).
118. Dharamshi, J. E. et al. Gene gain facilitated endosymbiotic evolution of Chlamydiae. *Nat. Microbiol.* **8**, 40–54 (2023).
119. Stelzner, K., Vollmuth, N. & Rudel, T. Intracellular lifestyle of *Chlamydia trachomatis* and host–pathogen interactions. *Nat. Rev. Microbiol.* **21**, 448–462 (2023).
120. Adouchief, S., Smura, T., Sane, J., Vapalahti, O. & Kurkela, S. Sindbis virus as a human pathogen—epidemiology, clinical picture and pathogenesis. *Rev. Med. Virol.* **26**, 221–241 (2016).
121. Strauss, J. H. & Strauss, E. G. The alphaviruses: gene expression, replication, and evolution. *Microbiol. Rev.* **58**, 806–806 (1994).
122. Stephens, R. S., Sanchez-Pescador, R., Wagar, E. A., Inouye, C. & Urdea, M. S. Diversity of *Chlamydia trachomatis* major outer membrane protein genes. *J. Bacteriol.* **169**, 3879–3885 (1987).
123. Nunes, A. et al. Evolutionary dynamics of ompA, the gene encoding the *Chlamydia trachomatis* key antigen. *J. Bacteriol.* **191**, 7182–7192 (2009).
124. Grieshaber, N. A. et al. The T3SS structural and effector genes of *Chlamydia trachomatis* are expressed in distinct phenotypic cell forms. *Front. Cell. Infect. Microbiol.* **15**, 1579247 (2025).
125. Belland, R. J. et al. Genomic transcriptional profiling of the developmental cycle of *Chlamydia trachomatis*. *Proc. Natl Acad. Sci. USA* **100**, 8478–8483 (2003).
126. Hakiem Owais, R., Rizvi Syed, M. A., Ramirez, C. & Tan, M. Euo is a developmental regulator that represses late genes and activates midcycle genes in *Chlamydia trachomatis*. *mBio* **14**, e00465–00423 (2023).
127. Mandel, C. et al. Expression and structure of the *Chlamydia trachomatis* DksA ortholog. *Pathog. Dis.* **80**, ftac007 (2022).
128. Dumoux, M., Clare, D. K., Saibil, H. R. & Hayward, R. D. Chlamydia assemble a pathogen synapse to hijack the host endoplasmic reticulum. *Traffic* **13**, 1612–1627 (2012).
129. Andrew, S. C., Dumoux, M. & Hayward, R. D. *Chlamydia* uses K<sup>+</sup> electrical signalling to orchestrate host sensing, inter-bacterial communication and differentiation. *Microorganisms* **9**, 173 (2021).
130. Kramer, G. et al. L23 protein functions as a chaperone docking site on the ribosome. *Nature* **419**, 171–174 (2002).
131. Zhang, D. J., Fan, H., McClarty, G. & Brunham, R. C. Identification of the *Chlamydia trachomatis* RecA-encoding gene. *Infect. Immun.* **63**, 676–680 (1995).
132. Szklarczyk, D. et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* **51**, D638–D646 (2023).
133. Garcia-Moreno, M. et al. System-wide profiling of RNA-binding proteins uncovers key regulators of virus infection. *Mol. Cell* **74**, 196–211.e111 (2019).
134. Kril, V. et al. Alphavirus nsP3 organizes into tubular scaffolds essential for infection and the cytoplasmic granule architecture. *Nat. Commun.* **15**, 8106 (2024).
135. Tan, Y. B. et al. Molecular architecture of the Chikungunya virus replication complex. *Sci. Adv.* **8**, eadd2536 (2022).
136. Dryga, S. A., Dryga, O. A. & Schlesinger, S. Identification of mutations in a Sindbis virus variant able to establish persistent infection in BHK cells: the importance of a mutation in the nsP2 gene. *Virology* **228**, 74–83 (1997).
137. Shin, G. et al. Structural and functional insights into alphavirus polyprotein processing and pathogenesis. *Proc. Natl Acad. Sci. USA* **109**, 16534–16539 (2012).
138. Frolov, I. et al. Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells. *J. Virol.* **73**, 3854–3865 (1999).
139. Frolova Elena, I. et al. Roles of nonstructural protein nsP2 and alpha/beta interferons in determining the outcome of Sindbis virus infection. *J. Virol.* **76**, 11254–11264 (2002).
140. Garmashova, N., Gorchakov, R., Frolova, E. & Frolov, I. Sindbis virus nonstructural protein nsP2 is cytotoxic and inhibits cellular transcription. *J. Virol.* **80**, 5686–5696 (2006).
141. Gao, Y., Goonawardane, N., Ward, J., Tuplin, A. & Harris, M. Multiple roles of the non-structural protein 3 (nsP3) alphavirus unique domain (AUD) during Chikungunya virus genome replication and transcription. *PLoS Pathog.* **15**, e1007239 (2019).
142. Qin, W. et al. Chemoproteomic profiling of itaconation by bioorthogonal probes in inflammatory macrophages. *J. Am. Chem. Soc.* **142**, 10894–10898 (2020).
143. Li, N., Lim, R. K. V., Edwardraja, S. & Lin, Q. Copper-free sonogashira cross-coupling for functionalization of alkyne-encoded proteins in aqueous medium and in bacterial cells. *J. Am. Chem. Soc.* **133**, 15316–15319 (2011).
144. Piersimoni, L., Kastiris, P. L., Arlt, C. & Sinz, A. Cross-linking mass spectrometry for investigating protein conformations and protein–protein interactions—a method for all seasons. *Chem. Rev.* **122**, 7500–7531 (2022).

145. Galan, S. R. G. et al. The minimum protein staple?—towards ‘bio’-Baldwin’s rules via inter-phosphosite linking in the MEK1 activation loop. *Chem. Sci.* **15**, 1306–1317 (2024).
146. Wang, S., Osgood, A. O. & Chatterjee, A. Uncovering post-translational modification-associated protein–protein interactions. *Curr. Opin. Struct. Biol.* **74**, 102352 (2022).
147. Lin, X. et al. A versatile method for site-specific chemical installation of aromatic posttranslational modification analogs into proteins. *J. Am. Chem. Soc.* **146**, 25788–25798 (2024).
148. Deng, Y., Finck, A. & Fan, R. Single-cell omics analyses enabled by microchip technologies. *Annu. Rev. Biomed. Eng.* **21**, 365–393 (2019).
149. Lin, Y.-C. et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. *Nat. Commun.* **5**, 4767 (2014).
150. Ishiyama, M., Miyazono, Y., Sasamoto, K., Ohkura, Y. & Ueno, K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. *Talanta* **44**, 1299–1305 (1997).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

## Methods

### In vitro protein S-arylation and choice of aryl iodide precursors

In a typical procedure, under air, a solution of cysteine-containing protein (15  $\mu\text{M}$ , 50  $\mu\text{l}$ ) in Tris buffer (20 mM, NaCl 150 mM, pH 8.0), was mixed with TMEDA-Ni-Ar(X) (5 mM in DMSO, 5 equiv., 0.75  $\mu\text{l}$ ) and incubated at 25 °C for 10 min. The reaction mixture was then purified by dialysis or size-exclusion chromatography. Representative results are shown from direct analysis by LC-MS.

An observed reactivity sequence of ArX towards Ni(COD)<sub>2</sub> of ArI > ArBr >> ArCl that necessitated use of neat ArCl and longer reaction times (>3 days at room temperature)<sup>37</sup> in reagent generation led us to focus instead largely on TMEDA-Ni-Ar(I), although use of a corresponding platform **2** (TMEDA)-Ni-Ar(Br), such as **2a** (TMEDA)-Ni-Ph(Br), also showed initial utility (see Supplementary Methods).

### *E. coli* 'pulse'-labelling protocol

*E. coli* BL21(DE3) cells were cultured in LB medium to an OD<sub>600</sub> of approximately 0.4, pelleted by centrifugation at 4,000g for 2 min at 4 °C, and washed three times with ice-cold PBS. Subsequently, the cells were resuspended in PBS followed by treatment with 1 mM **1a**, **1d** or **1f** for 1 h. After labelling, the cells were rinsed three times with phosphate-buffered saline (PBS) and collected by centrifugation at 4,000g for 5 min. Pellets were resuspended in 0.1% SDS in PBS buffer containing EDTA-free Pierce Halt protease inhibitor cocktail. Cells were lysed by sonication on ice, and cell lysates were collected by centrifugation (20,000g, 20 min) at 4 °C to remove debris. Protein concentration was determined via BCA protein assay. Then the samples were subjected to downstream SP3 clean-up, trypsin digestion and LC-MS/MS analysis.

### Mammalian cell 'pulse'-labelling protocol

CHO cells were seeded overnight in a 12-well plate. Before labelling, the medium was discarded and the cells were gently washed three times with Hanks' Balanced Salt Solution (HBSS). Then serially diluted **1f** probe in HBSS was added to the cells and incubated for 60 min, followed by cell lysis using RIPA buffer. The total protein content was quantified using the Pierce BCA Protein Assay Kit. The samples were subsequently adjusted to a concentration of 1 mg ml<sup>-1</sup>, followed by reaction with 1  $\mu\text{M}$  biotin-EG<sub>3</sub>-alkyne labelling reagent **1L** in the presence of 500  $\mu\text{M}$  triazole ligand (tris((1-hydroxy-propyl-1H-1,2,3-triazol-4-yl)methyl)amine, 95%, Merck catalogue number 678937), 100  $\mu\text{M}$  CuSO<sub>4</sub> and 2.5 mM sodium ascorbate, and incubated at 20 °C with agitation for 1 h. The resulting samples were then analysed using western blotting. SDS-PAGE gels were run and transferred onto a polyvinylidene difluoride membrane before blocking (TBS with 4% BSA and 0.1% Tween-20) for 1 h. The membrane was briefly rinsed (TBS and 0.1% Tween-20) before 1 h incubation with streptavidin HRP (Pierce High Sensitivity Streptavidin HRP, Thermo Scientific, catalogue number 21130, dilution 1:2,000) in TBS with 0.1% Tween-20 and then detection with enhanced chemiluminescence (Thermo Fisher Scientific SuperSignal West Femto Maximum Sensitivity Substrate, catalogue number 34094).

### Assessment of cytotoxicity

Cytotoxicity was assessed using the intracellular reduction of cell-permeable sodium 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8) to its corresponding water-soluble formazan as a proxy<sup>150</sup> using Cell Counting Kit-8 (WST-8/CCK-8, Abcam, ab228554).

In brief, 10,000–18,000 cells per well per 100  $\mu\text{l}$  were seeded overnight in a clear-bottom 96-well plate. Cells were then exposed to serially diluted analytes (for example, **1f** probe or IA-alkyne) or DMSO as a solvent control for specific time intervals. To ensure consistent DMSO concentrations across all wells and eliminate DMSO-related effects, **1f** (or IA-alkyne) was serially diluted in DMSO to prepare

1–40 mM stock solutions, and equal volumes of each were added to the wells. For blank wells (medium without cells), the same amount of DMSO was added. The solution was then replaced with fresh culture medium containing 10  $\mu\text{l}$  of WST-8 solution and incubated for 2 h in the dark at 37 °C. Absorbance at 460 nm was measured and normalized to vehicle-treated controls. Each group included four or five biological replicates. Two-way analysis of variance (ANOVA) was used to analyse the standard errors and assess statistical significance between groups. Essentially similar methods were used for other reagents (Supplementary Methods).

### Examination of cellular stress markers

Examination of five unfolded protein response (UPR)-induced proteins or protein modifications (PERK, IRE1 $\alpha$ -pSer724, ATF6 $\alpha$ , BiP and CHOP; Extended Data Fig. 8d) revealed that whilst expression levels of PERK and CHOP began to increase slightly after 1 h and some observable changes in IRE1-pS724 and ATF6 levels were observed after 2 h, in contrast to positive dithiothreitol (DTT) treatment, there was no loss of ATF6, and BiP levels remained unaffected by **1f** in HeLa cells. These results suggested only mild onset of ER stress and UPR after 1 mM treatment for 2 h, and without induction of cell death, consistent with retained viability in the prolonged time course assays. Together, these suggest a useful window under no- or only low-stress conditions even with 1 mM treatment of **1f**.

In brief, HeLa and HEK293T cells were seeded in six-well plates and cultured to ~80% confluency. Cells were then washed with prewarmed Dulbecco's phosphate-buffered saline (DPBS) and treated with 1 mM **1f** in HBSS (Gibco, catalogue number 14025092) for the indicated time points (0.5 h, 1 h or 2 h) at 37 °C. For negative control, cells received vehicle alone. For positive controls, cells were treated with either 2 mM DTT (2 h) or 30  $\mu\text{M}$  tunicamycin (Tm, 2 h) in HBSS. After treatment, cells were washed with ice-cold PBS and lysed in RIPA buffer containing EDTA-free Pierce Halt protease inhibitor cocktail (Thermo Scientific, catalogue number 78425). The cells were lysed by sonication in ice, and cell lysates were collected by centrifugation (20,000g, 30 min) at 4 °C to remove the debris. The protein concentration was determined by using the BCA protein assay kit. Equal amounts of protein were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membranes.

Western blotting was performed to detect UPR markers, including PERK, IRE1 $\alpha$ -pS724, BiP, ATF6 and CHOP. Membranes were blocked (TBS with 4% BSA and 0.1% Tween-20) and incubated with primary antibodies (PERK: Cell Signaling Technology, 3192; IRE1 $\alpha$ -pS724: Abcam, ab124945; BiP: Abcam, ab21685; ATF6: Abcam, ab122897; CHOP: Abcam, ab11419) overnight at 4 °C, followed by HRP-conjugated secondary antibodies. Chemiluminescent detection (enhanced chemiluminescence (Thermo Fisher Scientific SuperSignal West Femto Maximum Sensitivity Substrate, catalogue number 34094)) was used to visualize protein bands.

### Cysteine profiling via in situ protein labelling with **1f**

For the identification of Cys targets by **1f**, HEK293T cells were grown to 80% confluence in a 10-cm dish. The cells were washed once with prewarmed DPBS and then supplemented with 10 ml prewarmed HBSS. Cells were then treated with 1 mM **1f** or DMSO for 90 min, respectively. Cells were treated with 1 mM **1f** or an equivalent volume of DMSO for 90 min. To achieve a final concentration of 1 mM **1f**, a 30 mM stock solution of **1f** in DMSO was prepared, and 330  $\mu\text{l}$  of this stock was added to the 10 ml of HBSS, resulting in a final DMSO concentration of 3.3%. For the DMSO control, 330  $\mu\text{l}$  of DMSO was added to 10 ml of HBSS. The cells were washed with DPBS gently three times and collected by centrifugation at 300g for 3 min. The cell pellets were stored at -80 °C. The cell pellets were resuspended in ice-cold PBS buffer containing EDTA-free Pierce Halt protease inhibitor cocktail. The cells were lysed by sonication in ice, and cell lysates were collected by centrifugation (20,000g, 30 min) at 4 °C to remove the debris. The protein concentration was determined with the BCA protein assay kit.

Then, 1 ml of the **1f**-labelled cell lysates ( $2 \text{ mg ml}^{-1}$ ) was reacted with  $100 \mu\text{M}$  **L3** (PC Biotin-PEG3-alkyne, Broadpharm, bp-22677),  $100 \mu\text{M}$   $\text{CuSO}_4$ ,  $500 \mu\text{M}$  THPTA and  $2.5 \text{ mM}$  freshly prepared sodium ascorbate for 2 h at room temperature. The resulting mixture was precipitated by adding 8 ml methanol at  $-80^\circ\text{C}$  overnight. The precipitant was centrifuged ( $4^\circ\text{C}$ ,  $4,000\text{g}$ , 20 min), washed three times with 3 ml ice-cold methanol, and resuspended in 1 ml of 0.5% SDS followed by adding 0.6 ml of PBS (pH 7.4).

The biotinylated proteins were then captured by incubation with  $30 \mu\text{l}$  of neutravidin-coated magnetic particles (Cytiva, 78152104010150, prewashed with PBS) for 4 h at  $4^\circ\text{C}$  with gentle rotation. The beads were washed with the following buffer in order: 2% NP-40 in PBS (w/v, pH 7.4),  $0.3 \text{ M}$  NaCl in PBS (pH 7.4) and  $100 \text{ mM}$  ammonium bicarbonate in PBS (pH 7.4), three times. The resulting samples were resuspended with  $200 \mu\text{l}$   $100 \text{ mM}$  ammonium bicarbonate in PBS, followed by addition of  $25 \mu\text{l}$   $100 \text{ mM}$  DTT in water ( $65^\circ\text{C}$ , 15 min) and  $30 \mu\text{l}$   $200 \text{ mM}$  2-chloroacetamide in water ( $37^\circ\text{C}$ , 30 min, in the dark). After changing buffer with  $200 \mu\text{l}$  of  $100 \text{ mM}$  ammonium bicarbonate in PBS,  $1 \mu\text{l}$  of trypsin/LysC solution ( $0.1 \mu\text{g ml}^{-1}$  in trypsin resuspension buffer) was added and the resulting mixture was incubated at  $37^\circ\text{C}$  for 1 h. Then,  $1 \mu\text{l}$  of trypsin/LysC solution ( $0.1 \mu\text{g ml}^{-1}$ ) was added again and the mixture was incubated at  $37^\circ\text{C}$  for 4 h. The supernatants were collected for further identification of the modified proteins.

The beads were washed with  $200 \mu\text{l}$  1% DMSO in water (LC-MS grade) once and with  $200 \mu\text{l}$  water (LC-MS grade) six times. The beads were reconstituted in  $50 \mu\text{l}$  0.1% formic acid in water (v/v) and irradiated with  $15 \text{ J cm}^{-2}$  UV light at 365 nm. The supernatant was collected, the cleavage process was repeated and supernatant was combined. In addition, the beads were washed with 50% acetonitrile/water containing 1% formic acid ( $50 \mu\text{l}$ ), and the washes were combined with the supernatants to form the cleavage fraction. Sample was dried in a vacuum centrifuge and stored at  $-20^\circ\text{C}$  until analysis.

Peptide samples resuspended in 5% formic acid (FA)/0.015% *n*-dodecyl- $\beta$ -D-maltoside solution were loaded onto Eviotip Pure (Evosep Biosystems) according to the manufacturer's instructions, and then separated by high-pH reversed-phase chromatography on an Evosep One system (Evosep Biosystems) with the 30 samples-per-day method (44-min gradient), using a double-fritted in-house packed C18 Reprosil-Gold column ( $150 \mu\text{m}$  i.d.  $\times$   $150 \text{ mm}$  long,  $1.9\text{-}\mu\text{m}$  particle size, Dr Maisch) at  $500 \text{ nl min}^{-1}$ . Mobile phases A and B consisted of  $10 \text{ mM}$  of triethylammonium bicarbonate (TEAB, pH 8), and 100% acetonitrile, respectively. Eluted peptides were fractionated into a 96-well plate using a 3D-printer-based fraction collector, adapted from a Creativity Ender 5 S1 printer and powered by a Raspberry pi computer. The software is written in Python and uses PyGame for the GUI, Numpy for mathematical operations and PySerial for communication over USB. The list of components and instructions to build the fractionator can be found on GitHub via <https://github.com/garethnisbet/Fraction-Collection-Unit>. The 96-well plates were preloaded with  $47.5 \mu\text{l}$  of a solution composed by 5% FA/5% DMSO. Forty fractions were collected and automatically concatenated by the fraction collector into eight main fractions at 1-min intervals by combining fractions 1, 9, 17, 25, 33; 2, 10, 18, 26, 34; and so on. Concatenated fractions were subjected to low-pH LC-MS/MS analysis.

Peptides were separated on an Ultimate 3000 RSLCnano system (Thermo Fisher Scientific) equipped with a C-18 PepMap100 trap column ( $300 \mu\text{m}$  i.d.  $\times$   $5 \text{ mm}$  long,  $100 \text{ \AA}$ , Thermo Fisher Scientific) and an in-house packed Reprosil-Gold C-18 analytical column ( $50 \mu\text{m}$  i.d.  $\times$   $500 \text{ mm}$  long,  $1.9\text{-}\mu\text{m}$  particle size). Mobile phases (A: 0.1% FA, 5% DMSO, 94.9% water; B: 0.1% FA, 5% DMSO, 94.9% acetonitrile) were delivered at a flow rate of  $100 \text{ nl min}^{-1}$ . Fractionated samples were separated using 60-min gradients (10–33% B). Eluting peptides were electrosprayed into an Orbitrap Ascend Tribrid mass spectrometer (Thermo Fisher Scientific) using the data-dependent acquisition mode.

Full MS scans ( $350\text{--}1,400 \text{ m/z}$ ) were acquired in an Orbitrap analyser at 60,000 resolution with a  $1.2 \times 10^6$  automatic gain control target, and a 123-ms maximum injection time. The forty most intense precursors (charge states 2–7) from MS1 scans were selected and isolated at 1.2 Th with the quadrupole for the MS/MS event using higher-energy collision dissociation at a normalized collision energy of 26%, and the fragmentation spectra were detected by ion trap using the turbo scan rate mode ( $2 \times 10^4$  automatic gain control target ( $1 \times 10^4$ , 15-min gradient)) and a 32-ms maximum injection time. Dynamic exclusion was enabled for 20 s and the mass tolerance was  $\pm 10 \text{ ppm}$ .

Raw files from this study have been deposited to the ProteomeX-change Consortium via the PRIDE11 partner repository. The dataset output from Fragpipe and Maxquant that was further analysed with custom Python and R scripts is available on Zenodo<sup>151</sup>.

### Comparison with IAA

We compared the effectiveness of **1f** to that of one of the most currently widely used Cys-modification reagents, IAA. Exact head-to-head comparisons proved difficult due to the higher toxicity of IAA, which effectively prevented its use over  $100 \mu\text{M}$  (Extended Data Fig. 5a). Therefore, although our ability to use higher 'maximal' concentrations ( $1 \text{ mM}$  and greater) over longer times gave much greater reaction (Extended Data Fig. 5b), site identification (Extended Data Fig. 5c), intensities (Extended Data Fig. 5d) and coverage (Extended Data Fig. 5e) for **1f** compared with IAA, we also made further comparisons under submaximal conditions for **1f**. In a like-for-like 'practical' comparison we used  $100 \mu\text{M}$  of both reagents on the same amount of cells; use of **1f** generated on average 60% increase in the number of identified sites (Extended Data Fig. 5c). In addition, analysis of the cysteines identified by IAA and **1f** revealed that not only does **1f** give significantly more identifiable sites but that the overlap in identified sites between IAA and **1f** was very modest (Extended Data Fig. 5e) with a low correlation (Pearson  $r = 0.3\text{--}0.4$ ), despite good correlation between replicates in each experiment (Pearson  $r > 0.9$ ) (Extended Data Fig. 5f,g). This variability for IAA and seemingly very different selectivity could potentially be due to its toxicity. All of these experiments were still confounded in part by cell death for IAA and although we aimed to minimize this as much as possible (Supplementary Methods) we cannot therefore discount the fact that some of the peptides and proteins observed using IAA may come from dead cells. Next, given this varied distribution at like-for-like levels of  $100 \mu\text{M}$ , we opted to also make a further comparison of distributions starting with a much larger cellular sample for IAA (four dishes for IAA versus just one dish for **1f**). We felt that this might then allow IAA a mitigating distribution analysis that would compensate for the level of cell death/stress induced by IAA. However, even when probing four times as many cells (Extended Data Fig. 5c, column 3), IAA still proves inferior to use of **1f** from just one dish. By contrast, the reduced toxicity of **1f** allows use of even higher concentrations, leading to an increasing depth of sites that can be identified (Extended Data Fig. 5c, column 3). Together these data further confirmed that **1f** addresses a 'bottleneck' of toxicity and reactivity in current reagents that then allows application to access greater site number, depth and distribution.

### *C. trachomatis* infection and 'pulse'-labelling

HEK293 cells (ATCC, CRL-1573) were seeded at  $\sim 70\%$  confluency in 10-cm culture dishes, with each condition performed in triplicate. After 24 h, cells were infected with *C. trachomatis* LGV2 serovar at a MOI of  $< 0.1$  (MOI  $\approx 0.04$ , estimated from microscopy of infected versus uninfected cells across nine images), prepared by diluting bacterial stock in 10 ml of infection medium. To synchronize infection, cells were centrifuged at  $300\text{g}$  for 10 min at  $4^\circ\text{C}$  and subsequently incubated at  $37^\circ\text{C}$  with 5%  $\text{CO}_2$  for 80 min. Post-incubation, the infection medium was replaced with fresh medium, and cells were further incubated until labelling with **1f** compound at different time points. At 3 hpi,

8 hpi and 24 hpi, respectively, the infected cells were labelled with **1f** by replacing the existing medium with 10 ml HBSS containing 1 mM **1f** compound and further incubating for 60 min. The cells were then harvested by scraping and centrifuging to pellet the cells. The resulting pellets were resuspended in 500  $\mu$ l PBS supplemented with a protease inhibitor cocktail, sonicated for 10 min using an ultrasonic water bath and finally flash-frozen for storage until further analysis.

### SINV infection and ‘pulse’-labelling

HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (Gibco, 41965039) with 10% fetal bovine serum (Gibco, 10500064) and 1 $\times$  penicillin/streptomycin (Sigma Aldrich, P4458) at 37 °C with 5% CO<sub>2</sub>. BHK21 cells were used for growing virus stocks and maintained under the same conditions. SINV stock was generated by in vitro transcription from the pT7-SINV-wt plasmid and transfection into BHK21<sup>152</sup>. For pulse labelling, 8  $\times$  10<sup>6</sup> HEK293 cells were infected with SINV for 1 h in serum-free media at MOI = 3. The supernatant was replaced with 5% fetal bovine serum containing media, and incubated for 4, 8 or 18 h before treatment. At indicated time points, cells were washed once in 1 $\times$  PBS and incubated in prewarmed 10 ml HBSS containing 1 mM **1f** and further incubated for 60 min. After incubation, cells were scraped and centrifuged at 400g for 5 min at room temperature. Cell pellets were washed three times with 1 $\times$  PBS, snap-frozen in dry ice and stored at –80 °C.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Data that support the findings of this study are available in the Article and its Supplementary Information. The MS data for proteomics and modification site identification have been deposited to the ProteomeX-change Consortium through the PRIDE<sup>153</sup> partner repository, with the dataset identifiers [PXD053701](https://doi.org/10.1038/s41557-025-02017-1) and [PXD053749](https://doi.org/10.1038/s41557-025-02017-1). Crystallographic data for the structure reported in this Article have been deposited at the Cambridge Crystallographic Data Centre, under deposition number CCDC 2440276 (**1e**). Copies of the data can be obtained free of charge via <https://www.ccdc.cam.ac.uk/structures/>. Source data are provided with this paper.

### Code availability

Dataset output from Fragpipe and Maxquant was further analysed with custom Python and R scripts, available from Zenodo via <https://doi.org/10.5281/zenodo.12667586> (ref. 151).

### References

151. Liu, W. Biocompatible ‘ligand balancing’ in transition metal coordination allows benign in-cell protein arylation. *Zenodo* <https://doi.org/10.5281/zenodo.12667586> (2024).

152. Castelló, A., Sanz, M. Á, Molina, S. & Carrasco, L. Translation of Sindbis virus 26S mRNA does not require intact eukaryotic initiation factor 4G. *J. Mol. Biol.* **355**, 942–956 (2006).

153. Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. *Nucleic Acids Res.* **50**, D543–D552 (2021).

### Acknowledgements

We thank D. Mamalis for the supply of cAbVCAM1-Cys mutant and X. Zhang for technical assistance and access to facilities. W.K., V.R. and A.C. are funded by a European Research Council (ERC) Consolidator Grant (vRNP-capture, 101001634) and the UKRI-MRC (MC\_UU\_00034/2). R.T.R. and M.D. are supported by a Wellcome Trust Electrifying Life Sciences grant (220526/Z/20/Z). Next Generation Chemistry at the Rosalind Franklin Institute has been supported by grants from the UKRI-EPSC (EP/V011 359/1, EP/T012 021/1, EP/X527 245/1).

### Author contributions

W.L., X.F., S.M. and B.G.D. conceived and designed the project. X.F., W.L., X.Y., Y.J. and J.M. synthesized and characterized organonickel complexes. W.L., X.F. and C.-H.F. performed the protein conjugation reactions and associated cellular and biological experiments. W.L., Y.D., K.M.K. and E.K. carried out proteomics experiments and associated bioinformatics analyses. W.L., W.K., R.T.R., V.R. and M.N. conducted the pathogen-trapping experiments and analysed the data. All authors contributed to data interpretation. S.A., M.D., A.C., S.M. and B.G.D. directed the project. W.L., X.F. and B.G.D. wrote the manuscript with input from all authors. The equally contributing authors are listed alphabetically in the author list.

### Competing interests

The authors declare no competing interests.

### Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41557-025-02017-1>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41557-025-02017-1>.

**Correspondence and requests for materials** should be addressed to Shabaz Mohammed or Benjamin G. Davis.

**Peer review information** *Nature Chemistry* thanks Muhammad Jbara, Simon Lang and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.


**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



Extended Data Fig. 1 | See next page for caption.

**Extended Data Fig. 1 | Protein labelling in CHO cells by varying concentrations of **1f**.** **a)** Fluorescence confocal images of varying concentrations of **1f**. Tagged proteins were labelled with alkyne-Cy5 (red) via CuAAC. Hoechst 33342 was used to label nuclei of cells (blue). Representative data are shown from  $n = 3$  independent experiments with similar results. **b)** Immunoblot analyses of biotinylation confirmed labeling. CHO cells were treated with vehicle (first lane) or 1 mM **1f** (second and third lane) for 1 h. Cells were then lysed and left untreated or subjected to CuAAC with alkyne-(PEG)<sub>4</sub>-biotin. Signals observed in samples not treated with **1f** are attributed to endogenous biotinylation.


Representative data are shown from  $n = 3$  independent experiments with similar results. **c)** Schematic of Z-stack workflow. CHO cells were treated with **1f**, fixed, permeabilized and subjected to CuAAC with alkyne-Cy5, followed by confocal imaging and z-stack acquisition with a 0.35  $\mu\text{m}$  step. **d)** Representative confocal images of CHO cells treated with vehicle or **1f**. Proteins labelled were conjugated to Cy5 (red); nuclei were stained with Hoechst 33342 (blue). The boxed region was selected for z-stack analysis. Scale bar, 40  $\mu\text{m}$ . Data shown are from  $n = 3$  independent experiments with similar results. **e)** Seven representative images at different z-axis steps.



### Extended Data Fig. 2 | Validation of 1f labelling and neutravidin capture.

**a** HEK293T cells labeled with DMSO or **1f** (1 mM), followed by CuAAC with alkyne-PC-biotin L3. Labeling intensity determined by immunoblot analysis of biotinylation.  $\beta$ -actin demonstrates equal loading. Representative data are shown from  $n = 3$  independent experiments with similar results. **b** Proteins enriched with neutravidin beads resolved by SDS/PAGE and visualized by silver staining. L: **1f**-labeled; N: non-labeled. Input: Cell lysates before enrichment; IP1: proteins pulldown by neutravidin bead; IP2: Proteins eluted after UV cleavage; IP3: Protein residual on bead. Representative data are shown from  $n = 4$  independent experiments with similar results. **c** Volcano plot displaying the average  $\log_2$  fold change (x-axis, **1f**-labeled vs non-labeled) for the proteins and their  $P$  values (y-axis) (generated from Perseus 1.6.15.0). **d** Hyperscore

distribution plots illustrate the fraction of hyperscores of sites. Left: Non-Cys hits (Asp, Glu, Ser, Gln, Thr) and Right: Cys hits. In one analysis, estimated that the limits of selectivity are >90% for Cys and the plot shown is based on the remaining 9.6% of hits. These are poorly located and/or potentially wrong matches. Under this analysis, this represents the limits of our precision in estimating selectivity. It should be noted that no high-quality spectra are yielded from these remaining sets but are discounted simply for consistency. The number of spectra obtained in this study precluded manual annotation but, on the basis that no other type of chemoselectivity could be confirmed with high certainty, it suggests that these values for Cys selectivity may be far greater and further analyses indicated selectivities up to >98% (see Supplementary Note 2).



### Extended Data Fig. 3 | Bioinformatic analysis of 1f-modified proteins.

**a)** Molecular function analysis of the targets with 1f-modified sites. **b)** Biological process analysis of the targets with 1f-modified sites. **c)** Cellular component analysis of the targets with 1f-modified sites. **d)** Sequence logos around sites modified by 1f shown using IceLogo. Position 16 indicates the modified site. The y-axis shows the % difference over p value = 0.01. No clear motif patterns are seen


beyond the expected biases of Cys depletion from Cys reactivity.

**e)** Accessibility distributions for amino acids across the 1f-labelled protein datasets. Amino acid pPSE distributions were normalized to proteome-wide average for all residues. Amino acids are ordered by percentage exposed (pPSE < 5) residues. **f)** Accessibility distributions of 1f-labeled cysteine residues.



**Extended Data Fig. 4 | Analysis of 1f-modified cysteine residues.** **a)** Pie charts illustrating the percentage of 1f-modified proteins with functionally annotated 'active sites' in UniProt. Among the 606 active sites in the 414 proteins, 13 cysteine active site nucleophiles are modified by 1f. **b)** Pie charts illustrating the percentage of 1f-modified proteins with functionally annotated 'binding sites' in UniProt. Among the 4,735 binding sites in the 826 proteins, 117 cysteine metal binding sites are modified by 1f. **c)** Pie charts illustrating the percentage of 1f-modified proteins with functionally annotated 'zinc finger' in UniProt. Among the 917 zinc finger sites in the 309 proteins, 144 cysteine zinc finger sites are modified by 1f. **d)** Pie charts illustrating the percentage of 1f-modified proteins with functionally annotated 'mutagenesis' in UniProt. Among the 6,791 mutagenesis sites in the 1074 proteins, 121 cysteine mutagenesis sites


are modified by 1f. **e)** The overlap between cysteines from the total 19 public datasets (combined in cell plus in vitro lysate cysteine profiling, black) and those targeted by 1f in situ (red). **f)** The overlap between proteins from the total 19 public datasets (combined in cell plus in vitro lysate cysteine profiling, black) and those identified by 1f in situ (red). **g)** Histogram plot showing the distribution of distances: (1) between 1f-labelled cysteine residues and active sites (top), and (2) between all cysteine residues and active sites (bottom). The essentially identical distribution suggests broadly even reactivity and no strong bias towards active site residues. **h)** Circular bar plot showing the distances within active sites that are equal to 0 Å (red) and within 2.5 Å (blue) or 5 Å (black) of active sites. Again, an essentially unbiased distribution is observed suggesting a striking potential to broadly modify Cys residues across the proteome.



Extended Data Fig. 5 | See next page for caption.

**Extended Data Fig. 5 | Head-to-head benchmarking of **1f** biolabeling against IAA in living cells.** **a**) Cell viability of HEK293T cells after 30 min incubation with IAA at various concentrations by WST-8 assay. Error bars represent the standard deviation (s.d.) from  $n = 4$  independent biological replicates. **b**) Immunoblot analysis of biotinylation by IAA (100  $\mu\text{M}$ ) or **1f** probe (100  $\mu\text{M}$  and 1,000  $\mu\text{M}$ ) labeling. Negative control cells received vehicle alone. HEK-293 cells were labeled with IAA for 0.5 h or **1f** for 1 h in HBSS at the indicated concentrations. Cells were then lysed and subjected to CuAAC ligation with alkyne-PC-biotin L3 (for **1f** samples) or azide-PC-biotin (for IAA samples). Labeled proteins were visualized by immunoblot analysis of biotinylation, with  $\beta$ -actin serving as a loading control. Representative data are shown from  $n = 3$  independent experiments with similar results. **c**) Comparisons of IAA with **1f** across 'practical' like-for-like (100  $\mu\text{M}$ ) and 'maximal' (1000  $\mu\text{M}$  for **1f**) conditions show that use of **1f** identifies a greater number of sites (column 1 vs column 2). Even with use of four times as


many cells from four dishes (column 3), IAA still proves inferior to use of **1f** from just one dish. By contrast, the reduced toxicity of **1f** allows use of even higher concentrations leading to a continuing depth of sites that can be identified (column 4). FragPipe's 'closed' search was used here. Error bars represent the standard deviation (s.d.) from  $n = 3$  independent biological replicates. Exact p values shown (one-way ANOVA). **d**) IAA- and **1f**- modified peptide intensities from  $n = 3$  independent experiments from. **e**) Overlap of cysteine sites labeled by IAA (1 dish, blue; 4x: 4 dishes, green) and **1f** (100  $\mu\text{M}$ , purple; 1,000  $\mu\text{M}$ , pink) in live cells. Labelled sites detected in at least one biological replicate for each condition are categorized. **f**) Correlation matrix between replicates and conditions. **g**) Correlation of average intensities from IAA (100  $\mu\text{M}$ ) vs **1f** (1,000  $\mu\text{M}$ ). The statistical significance of correlations was determined using Pearson's correlation coefficient. The linear regression curve is shown as a black line.



Extended Data Fig. 6 | See next page for caption.


**Extended Data Fig. 6 | Analysis of the dependence of reactivity on Cys oxidation state. a)** Fold change of **1f**-modified intensity after forced reduction. The opening of diverse disulfides in native BSA leads to a reduction in labeling intensity at primary initial free Cys site 58 and observed modifications at many other free Cys, consistent with a need for free Cys as reactant with **1f**. **b)** LC-MS analysis of reactivity of **1f** with CabVCAM-C118 under different redox states: native oxidized (low levels of free Cys and one *intra*-molecular disulfide plus *inter*-molecular disulfides), mildly reduced monomer (2 equivalents of TCEP to reduce *inter*-molecular disulfide giving one free Cys and one *intra*-molecular

disulfide), and 'forced' reduced CabVCAM-C118 (40 equiv of TCEP giving up to three free Cys). **c)** Fold change of **1f**-modified intensity after forced reduction. Forced reduction of CabVCAM-C118 enabled higher levels of multi-site modification. **d)** Only tri-oxidation showed any genuine enrichment to cysteines beyond proteome frequency. PSMs with tri-oxidation contained multiple cysteines and vitally modification with either chloroacetamide (during sample preparation) or **1f** (in-cell chemistries), consistent with them being only mutually exclusive with tri-oxidation.




**Extended Data Fig. 7 | Test of 1a, 1d, 1f cellular reactivity without affinity retrieval to assess broader reactivity of this family of reagents. a** Schematic showing *E. coli* cell labelling and direct observation without affinity retrieval by LC-MS/MS analysis. **b** Venn diagram showing the overlap of labeled cysteine

sites obtained with compound 1a, 1d, or 1f. This suggests that the relative in-cell reactivity of 1f is in-between that of 1a or 1d. **c** Representative tandem mass spectra of selected peptide precursors labeled by the reagents in-cell.




**Extended Data Fig. 8 | Extended Toxicity Tests and Analysis of Cellular Stress Markers.** **a**) Cell viability of HeLa and HEK293T cells after incubation with **1f** at 1 mM at various time points. Cell viability was assessed through WST-8 reagent and measure the absorbance at 460 nm. The absorbances was normalized to vehicle-treated cells. Individual data points are shown. Error bars represent the standard deviation (s.d.) from  $n = 4$  independent replicates. **b**) Cell viability and solubility assessment of Pd reagents. on HEK293T cells. Error bars represent the standard deviation (s.d.) from  $n = 4$  independent replicates. (see Supplementary Tables S3 for exact P values). \*\*\*\* $p < 0.0001$ , \*\*\* $p < 0.001$ , \*\* $p < 0.01$ , \* $p < 0.05$ , ns, not significant (two-way ANOVA). **c**) Cell viability and solubility assessment of a putative comparable Ni(0) source. Although the exact intracellular concentration of Ni(0) after C–S bond formation is unknown, we also tested the direct toxicity of Ni(COD)<sub>2</sub> in HEK293T cells as a representative Ni(0) complex. Cell viability remains above 80% at 0.2 mM Ni(0), and apparent toxicity is observed only at  $\geq 0.5$  mM. When taken with the observations that **1f** concentration used was typically 1 mM; more limited cellular uptake of

reagents is likely, and that lower toxicity was observed for **1f** than Ni(COD)<sub>2</sub>, then it is likely that, intracellular Ni(0) concentration resulting from reactions will be much lower than 500  $\mu$ M and so not an obvious driver of toxicity. The photographic insets also highlight the air-sensitivity and instability in aqueous environments of Ni(COD)<sub>2</sub>; Ni black was observed during the stock preparation and cell incubation. Error bars represent the standard deviation (s.d.) from  $n = 4$  independent replicates. **d**) Monitoring of UPR activation markers in **1f**-treated HeLa cells and HEK-293T cells. Negative control cells received vehicle alone. Cells were exposed to 1 mM **1f** in HBSS for the indicated times. Positive control cells were exposed to 2 mM DTT or 30  $\mu$ M tunicamycin in HBSS for 2 h, as indicated. The expression levels of UPR marker proteins were measured by Western blot in whole cell lysates. As loading controls, membranes were stripped and reprobed for  $\beta$ -actin. ATF6-FL/G, full-length glycosylated ATF6; ATF6-FL/UG, full-length unglycosylated ATF6; ATF6(N), cleaved ATF6. Representative data are shown from  $n = 2$  independent experiments with similar results.



**Extended Data Fig. 9 | Workflow and Extended Analyses of Infection Studies and Pathogen trapping with ligand-balanced aryl-nickel 1f.** **a)** Workflow showing pathogen infection and site mapping in HEK293 cells. **b)** Immunoblot analysis confirms labeling of *C. trachomatis*-infected cells by **1f**, followed by tagging with biotin labelling reagent **13** using CuAAC.  $\beta$ -actin demonstrates equal loading. Representative data are shown from  $n = 3$  independent experiments with similar results. **c)** Time-course intensities of **1f**-labeled *C. trachomatis* proteins. **d)** Time-course intensities of all emerging *C. trachomatis* proteins in whole cell lysate. At 24 hpi, 175 *C. trachomatis* proteins were detected. Proteins detected in

the mock-infected samples are likely false positives, potentially human proteins that were misidentified due to sequence homology. **e)** Correlation matrix of protein abundances across replicates and conditions in whole cell lysates of *Chlamydia*-infected cells (1  $\mu$ g 120 min DIA Ascend). **f)** Immunoblot analysis confirms labeling of SINV-infected cells by **1f**. Representative data are shown from  $n = 3$  independent experiments with similar results. **g)** Correlation matrix of protein abundances across replicates and conditions in WCL of SINV-infected cells (1  $\mu$ g 120 min DIA Ascend). Protein quantification was performed with FragPipe-DIA and DIA-NN.



**Extended Data Fig. 10 | The Effect of Filtering Peptide Spectrum Matches by Identification quality parameters on Site Localisation.** **a**) Distribution of score differences between top two hits in proportion to the total score (DeltaScore). **b**) Distribution of peptide identification probability. **c-e**) Proportion of

peptide spectrum matches localised to cysteine when filtered by length and neighbouring residues (**c**, 25521 psms), also by DeltaScore >2.5% and match probability >0.99 (**d**, 11138 psms), and all of the above only for 2+ precursors (**e**, 4317 psms).

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a                                 | Confirmed  |
|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of all covariates tested  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

- |                 |  |
|-----------------|--|
| Data collection | Data was collected using the software provided by the respective instrument vendor and is specified in the Methods section.  |
| Data analysis   | Data was analysed with MassLynx 4.2 (Waters), GraphPad Prism 10 (GraphPad Software Inc.), MestReNova-14.1.1-24571 (Mestrelab Research S.L.), Microsoft Excel 16 (Microsoft, version 16.0.17830.20056), MaxQuant (v.2.3.0.0), MSFragger-based FragPipe (FragPipe interface (v21.1) was used with MSFragger (version: 4.0), Philosopher (version: 5.1.0), IonQuant (version 1.10.12)4 and Python (version: 3.9.18) enabled), AlphaFold 2(open source, version 2.0). Protein subcellular localization analysis was enabled by Gene Ontology (GO) analysis from DAVID Bioinformatics Resources. Data processing were performed using Image Lab (Bio-Rad Laboratories v6.1), ImageJ (1.54d), Python (3.10.11) and R (open source, 4.4.0). |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The mass spectrometry data for proteomics and modification site identification have been deposited to the ProteomeXchange Consortium through the PRIDE partner repository, with the dataset identifier PXD053701 and PXD053749.

Dataset output from Frappipe and Maxquant was further analyzed with custom Python and R scripts, available on Zenodo at <https://doi.org/10.5281/zenodo.12667586>.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

### Reporting on sex and gender

*Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data where this information has been collected, and consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.*

### Population characteristics

*Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."*

### Recruitment

*Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.*

### Ethics oversight

*Identify the organization(s) that approved the study protocol.*

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences     Behavioural & social sciences     Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

### Sample size

Sample sizes (typically  $n = 3-6$  biologically independent replicates) were chosen based on standard practice in chemical biology and prior publications reporting similar effect sizes. These numbers were sufficient to ensure statistical significance and reproducibility across independent experiments. Toxicity testing assays were conducted with  $n=4$  or  $5$ . The exact number of replicates is reported in the supplementary information for each experiment. Fluorescence confocal microscopy quantification was conducted with at least  $n=9$ . Validation of 1f labelling and LC-MS/MS analysis was conducted as biological replicates with  $n=3$ . Synthetic reactions and protein modifications were carried out independently for multiple times and proved to be reliable and consistent. The reported values for conversion and yield should be regarded as semi-quantitative.

### Data exclusions

No data was excluded.

### Replication

All key findings were independently replicated at least two times with consistent results. No findings failed replication. For fluorescent gel imaging, confocal imaging, western blots as well as proteomics experiments were repeated at least three times with similar results and one representative result was shown in the study.

### Randomization

Potential covariates such as cell passage number, reagent batch, and incubation time were controlled by standardizing protocols across all experiments. All treatments were randomized and performed in parallel to minimize batch effects, including Western blots, in-gel

fluorescence scanning, and confocal imaging cannot be randomized. However, during the proteomics study, various samples (including 1f-labeled and vehicle, with both technical and biological replicates) were processed concurrently without any specific preference or bias. Throughout the sample preparation, careful attention was paid to ensure consistent treatment of sample batches by rotating the order of samples during repeated processing steps. During mass spectrometric measurements, liquid chromatography columns were routinely cleaned between runs, and replicate samples from the same experimental set were injected in a random order to prevent measurement biases. Additionally, batch effects and experimental biases were further minimized during downstream computational analyses through normalization and cross-validation of the dataset.

## Blinding

For all experiments, including imaging assays, gels, blots, and proteomic data were collected and analyzed without bias.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

- |                                     |   |
|-------------------------------------|---|
| n/a                                 | Involved in the study                                     |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Antibodies            |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology    |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms      |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data                    |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern     |

### Methods

- |                                     |   |
|-------------------------------------|---|
| n/a                                 | Involved in the study                           |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq               |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry         |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

## Antibodies

### Antibodies used

Streptavidin HRP: Pierce High Sensitivity Streptavidin HRP, Thermo Scientific, catalogue number 21130;  
 beta Actin Loading Control Monoclonal Antibody (BA3R): Thermo Scientific, Catalog # MA5-15739;  
 Anti-Mouse IgG (H+L), HRP Conjugate: promega, Catalog number selected: W4021;  
 PERK: Cell Signaling Technology, #3192;  
 IRE1 $\alpha$ -pS724: Abcam, ab124945;  
 BIP: Abcam, ab21685;  
 ATF6: Abcam, ab122897;  
 CHOP: Abcam, ab11419.  
 Dilutions and incubation time according to the manufacturer's instructions on the supplier's website.

### Validation

Streptavidin HRP, Detection Method: Colorimetric, Chemiluminescent, Chemifluorescent, Specificity: Biotin, For Use With (Application): Western Blotting, ELISA  
<https://www.thermofisher.com/order/catalog/product/21130?SID=srch-srp-21130>

beta Actin Loading Control Monoclonal Antibody (BA3R): Advanced Verification, this Antibody was verified by Knockout to ensure that the antibody binds to the antigen stated. Published species: Chicken, Fungi, Guinea pig, Hamster, Human, Mouse, Non-human primate, Pig, Plant, Rabbit, Rat, Xenopus  
<https://www.thermofisher.com/antibody/product/beta-Actin-Loading-Control-Antibody-clone-BA3R-Monoclonal/MA5-15739>

Anti-Mouse IgG (H+L), HRP Conjugate Applications Western blotting. Enzyme-linked immunosorbent assay (ELISA). Dot blotting.  
[https://www.promega.co.uk/products/protein-detection/primary-and-secondary-antibodies/anti\\_mouse-igg-h-and-l-hrp-conjugate/?catNum=W4021](https://www.promega.co.uk/products/protein-detection/primary-and-secondary-antibodies/anti_mouse-igg-h-and-l-hrp-conjugate/?catNum=W4021)

PERK: Cell Signaling Technology, #3192: 710 Citations using this antibody, <https://www.cellsignal.com/products/primary-antibodies/perk-c33e10-rabbit-mab/3192>

IRE1 $\alpha$ -pS724: Abcam, ab124945: 118 publications using this antibody, <https://www.abcam.com/en-us/products/primary-antibodies/ire1-phospho-s724-antibody-epr5253-ab124945>

BIP: Abcam, ab21685: 646 publications using this antibody, <https://www.abcam.com/en-us/products/primary-antibodies/grp78-bip-antibody-ab21685>

ATF6: Abcam, ab122897: 70 publications using this antibody, <https://www.abcam.com/en-us/products/primary-antibodies/atf6-antibody-1-7-ab122897>

CHOP: Abcam, ab11419: 237 publications using this antibody, <https://www.abcam.com/en-us/products/primary-antibodies/chop-antibody-9c8-ab11419>

## Eukaryotic cell lines

---

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	HEK293T, HEK293, CHO and HeLa cell lines were obtained from ATCC (CRL-3216, CRL-1573, CCL-61, and CRM-CCL-2).
Authentication	The cell lines were authenticated by STR analysis by ATCC.
Mycoplasma contamination	All cells used were tested negative for mycoplasma. Mycoplasma testing is performed monthly.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No commonly misidentified cell lines were used in these studies.